F. Hoffmann-La Roche AG, CH-4070 Basel, Switzerland Case: P37765 NEW HETEROCYCLIC COMPOUNDS Field of the Invention The present invention relates to organic compounds useful for therapy or prophylaxis in a mammal, and in particular to monoacylglycerol lipase (MAGL) inhibitors for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, inflammatory bowel disease, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal. Background of the Invention Endocannabinoids (ECs) are signaling lipids that exert their biological actions by interacting with cannabinoid receptors (CBRs), CB1 and CB2. They modulate multiple physiological processes including neuroinflammation, neurodegeneration and tissue regeneration (Iannotti, F.A., et al., Progress in lipid research 2016, 62, 107-28.). In the brain, the main endocannabinoid, 2-arachidonoylglycerol (2-AG), is produced by diacyglycerol lipases (DAGL) and hydrolyzed by the monoacylglycerol lipase, MAGL. MAGL hydrolyses 85% of 2-AG; the remaining 15% being hydrolysed by ABHD6 and ABDH12 (Nomura, D.K., et al., Science 2011, 334, 809.). MAGL is expressed throughout the brain and in most brain cell types, including neurons, astrocytes, oligodendrocytes and microglia cells (Chanda, P.K., et al., Molecular pharmacology 2010, 78, 996; Viader, A., et al., Cell reports 2015, 12, 798.).2-AG hydrolysis results in the formation of arachidonic acid (AA), the precursor of prostaglandins (PGs) and leukotrienes (LTs). Oxidative metabolism of AA is increased in inflamed tissues. There are two principal enzyme pathways of arachidonic acid oxygenation involved in inflammatory processes, the cyclo- oxygenase which produces PGs and the 5-lipoxygenase which produces LTs. Of the various cyclooxygenase products formed during inflammation, PGE2 is one of the most important. These products have been detected at sites of inflammation, e.g. in the CNE/13.10.2023 cerebrospinal fluid of patients suffering from neurodegenerative disorders and are believed to contribute to inflammatory response and disease progression. Mice lacking MAGL (Mgll-/-) exhibit dramatically reduced 2-AG hydrolase activity and elevated 2-AG levels in the nervous system while other arachidonoyl-containing phospho- and neutral lipid species including anandamide (AEA), as well as other free fatty acids, are unaltered. Conversely, levels of AA and AA-derived prostaglandins and other eicosanoids, including prostaglandin E2 (PGE2), D2 (PGD2), F2 (PGF2), and thromboxane B2 (TXB2), are strongly decreased. Phospholipase A2 (PLA2) enzymes have been viewed as the principal source of AA, but cPLA ₂ -deficient mice have unaltered AA levels in their brain, reinforcing the key role of MAGL in the brain for AA production and regulation of the brain inflammatory process. Neuroinflammation is a common pathological change characteristic of diseases of the brain including, but not restricted to, neurodegenerative diseases (e.g. multiple sclerosis, Alzheimer’s disease, Parkinson disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy and mental disorders such as anxiety and migraine). In the brain, production of eicosanoids and prostaglandins controls the neuroinflammation process. The pro-inflammatory agent lipopolysaccharide (LPS) produces a robust, time- dependent increase in brain eicosanoids that is markedly blunted in Mgll–/– mice. LPS treatment also induces a widespread elevation in pro-inflammatory cytokines including interleukin-1-a (IL-1-a), IL-1b, IL-6, and tumor necrosis factor-a (TNF-a) that is prevented in Mgll–/– mice. Neuroinflammation is characterized by the activation of the innate immune cells of the central nervous system, the microglia and the astrocytes. It has been reported that anti- inflammatory drugs can suppress in preclinical models the activation of glia cells and the progression of disease including Alzheimer’s disease and mutiple sclerosis (Lleo A., Cell Mol Life Sci.2007, 64, 1403.). Importantly, genetic and/or pharmacological disruption of MAGL activity also blocks LPS-induced activation of microglial cells in the brain (Nomura, D.K., et al., Science 2011, 334, 809.). In addition, genetic and/or pharmacological disruption of MAGL activity was shown to be protective in several animal models of neurodegeneration including, but not restricted to, Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. For example, an irreversible MAGL inhibitor has been widely used in preclinical models of neuroinflammation and neurodegeneration (Long, J.Z., et al., Nature chemical biology 2009, 5, 37.). Systemic injection of such inhibitor recapitulates the Mgll-/- mice phenotype in the brain, including an increase in 2-AG levels, a reduction in AA levels and related eicosanoids production, as well as the prevention of cytokines production and microglia activation following LPS-induced neuroinflammation (Nomura, D.K., et al., Science 2011, 334, 809.), altogether confirming that MAGL is a druggable target. Consecutive to the genetic and/or pharmacological disruption of MAGL activity, the endogenous levels of the MAGL natural substrate in the brain, 2-AG, are increased.2-AG has been reported to show beneficial effects on pain with, for example, anti-nociceptive effects in mice (Ignatowska-Jankowska B. et al., J. Pharmacol. Exp. Ther.2015, 353, 424.) and on mental disorders, such as depression in chronic stress models (Zhong P. et al., Neuropsychopharmacology 2014, 39, 1763.). Furthermore, oligodendrocytes (OLs), the myelinating cells of the central nervous system, and their precursors (OPCs) express the cannabinoid receptor 2 (CB2) on their membrane. 2-AG is the endogenous ligand of CB1 and CB2 receptors. It has been reported that both cannabinoids and pharmacological inhibition of MAGL attenuate OLs’s and OPCs’s vulnerability to excitotoxic insults and therefore may be neuroprotective (Bernal-Chico, A., et al., Glia 2015, 63, 163.). Additionally, pharmacological inhibition of MAGL increases the number of myelinating OLs in the brain of mice, suggesting that MAGL inhibition may promote differentiation of OPCs in myelinating OLs in vivo (Alpar, A., et al., Nature communications 2014, 5, 4421.). Inhibition of MAGL was also shown to promote remyelination and functional recovery in a mouse model of progressive multiple sclerosis (Feliu A. et al., Journal of Neuroscience 2017, 37 (35), 8385.). In recent years, metabolism is talked highly important in cancer research, especially the lipid metabolism. Researchers believe that the de novo fatty acid synthesis plays an important role in tumor development. Many studies illustrated that endocannabinoids have anti-tumorigenic actions, including anti-proliferation, apoptosis induction and anti- metastatic effects. MAGL as an important decomposing enzyme for both lipid metabolism and the endocannabinoids system, additionally as a part of a gene expression signature, contributes to different aspects of tumourigenesis, including in glioblastoma (Qin, H., et al., Cell Biochem. Biophys.2014, 70, 33; Nomura DK et al., Cell 2009, 140(1), 49-61; Nomura DK et al., Chem. Biol.2011, 18(7), 846-856, Jinlong Yin et al, Nature Communications 2020, 11, 2978). The endocannabinoid system is also invlolved in many gastrointestinal physiological and physiopathological actions (Marquez, Suarez et al.2009). All these effects are driven mainly via cannabinoid receptors (CBRs), CB1 and CB2. CB1 receptors are present throughout the GI tract of animals and healthy humans, especially in the enteric nervous system (ENS) and the epithelial lining, as well as smooth muscle cells of blood vessels in the colonic wall (Wright, Rooney et al.2005), (Duncan, Davison et al.2005). Activation of CB1 produces anti-emetic, anti-motility, and anti-inflammatory effect, and help to modulate pain (Perisetti, Rimu et al.2020). CB2 receptors are expressed in immune cells such as plasma cells and macrophages, in the lamina propria of the GI tract (Wright, Rooney et al.2005), and primarily on the epithelium of human colonic tissue associated with inflammatory bowel disease (IBD). Activation of CB2 exerts anti-inflammatory effect by reducing pro-inflammatory cytokines. Expression of MAGL is increased in colonic tissue in UC patients (Marquez, Suarez et al.2009) and 2-AG levels are increased in plasma of IBD patients (Grill, Hogenauer et al.2019). Several animal studies have demonstrated the potential of MAGL inhibitors for symptomatic treatment of IBD. MAGL inhibition prevents TNBS-induced mouse colitis and decreases local and circulating inflammatory markers via a CB1/CB2 MoA (Marquez, Suarez et al.2009). Furthermore, MAGL inhibition improves gut wall integrity and intestinal permeability via a CB1 driven MoA (Wang, Zhang et al.2020). In conclusion, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, inflammatory bowel disease, abdominal pain and abdominal pain associated with irritable bowel syndrome. Furthermore, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for providing neuroprotection and myelin regeneration. Accordingly, there is a high unmet medical need for new MAGL inhibitors. Summary of the Invention In a first aspect, the present invention provides compounds of formula (I) ^B _A (I) wherein A, B, L, W, Y, Z, and R ¹ to R ³ are as defined herein. In further aspects, the invention provides compositions including the compounds of formula (I), processes of manufacturing the compounds of formula (I) and methods of using the compounds of formula (I). Detailed Description of the Invention Definitions Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein, unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed. The term “alkyl” refers to a mono- or multivalent, e.g., a mono- or bivalent, linear or branched saturated hydrocarbon group of 1 to 6 carbon atoms (“C _1-6 -alkyl”), e.g., 1, 2, 3, 4, 5, or 6 carbon atoms. In some embodiments, the alkyl group contains 1 to 4 carbon atoms, e.g., 1, 2, 3, or 4 carbon atoms. In other embodiments, the alkoxy group contains 1 to 3 carbon atoms. Some non-limiting examples of alkyl include methyl, ethyl, propyl, 2- propyl (isopropyl), n-butyl, iso-butyl, sec-butyl, tert-butyl, and 2,2-dimethylpropyl. Particularly preferred, yet non-limiting examples of alkyl are methyl, tert-butyl, and 2,2- dimethylpropyl. The term “alkoxy” refers to an alkyl group, as previously defined, attached to the parent molecular moiety via an oxygen atom. Unless otherwise specified, the alkoxy group contains 1 to 6 carbon atoms (“C _1-6 -alkoxy”). In some embodiments, the alkoxy group contains 1 to 4 carbon atoms, e.g., 1, 2, 3, or 4 carbon atoms. In other embodiments, the alkoxy group contains 1 to 3 carbon atoms. Some non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy. A particularly preferred, yet non-limiting example of alkoxy is methoxy. The term “cycloalkylalkyl” refers to a cycloalkyl group, as previously defined, attached to the parent molecular moiety via an alkyl group. A particularly preferred, yet non-limiting example of cycloalkylalkyl is cyclopropylmethyl. The term “halogen” or “halo” refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I). Preferably, the term “halogen” or “halo” refers to fluoro (F), chloro (Cl) or bromo (Br). Particularly preferred, yet non-limiting examples of “halogen” or “halo” are fluoro (F) and chloro (Cl). The term “cycloalkyl” as used herein refers to a saturated monocyclic or bicyclic hydrocarbon group of 3 to 10 ring carbon atoms (“C _3-10 -cycloalkyl”). In some preferred embodiments, the cycloalkyl group is a monocyclic hydrocarbon group of 3 to 8 ring carbon atoms. “Bicyclic cycloalkyl” refers to cycloalkyl moieties consisting of two saturated carbocycles having two carbon atoms in common, i.e., the bridge separating the two rings is either a single bond or a chain of one or two ring atoms, and to spirocyclic moieties, i.e., the two rings are connected via one common ring atom. Preferably, the cycloalkyl group is a monocyclic hydrocarbon group of 3 to 6 ring carbon atoms, e.g., of 3, 4, 5 or 6 carbon atoms. Some non-limiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-bicyclo[1.1.1]pentanyl, norbornanyl, and 1-bicyclo[2.2.2]octanyl. A particularly preferred, yet non-limiting example of cycloalkyl is cyclopropyl. The term "aryl" refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of 6 to 14 ring members (“C6-C14-aryl”), preferably 6 to 12 ring members, and more preferably 6 to 10 ring members, and wherein at least one ring in the system is aromatic. Some non-limiting examples of aryl include phenyl and 9H-fluorenyl (e.g.9H- fluoren-9-yl). A particularly preferred, yet non-limiting example of aryl is phenyl. The term “hydroxy” refers to an –OH group. The term “cyano” refers to a –CN (nitrile) group. The term “sulfamoyl” refers to a group H ₂ N-SO ₂ –. The term “haloalkyl” refers to an alkyl group as defined herein, wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a halogen atom, preferably fluoro. Preferably, “haloalkyl” refers to an alkyl group wherein 1, 2 or 3 hydrogen atoms of the alkyl group have been replaced by a halogen atom, most preferably fluoro. Particularly preferred, yet non-limiting examples of haloalkyl are trifluoromethyl, difluoromethyl, 1,1- difluoroethyl, 2,2-difluoroethyl, and 2,2,2-trifluoroethyl. The term “halocycloalkyl” refers to a cycloalkyl group as defined herein, wherein at least one of the hydrogen atoms of the cycloalkyl group has been replaced by a halogen atom, preferably fluoro. Preferably, “halocycloalkyl” refers to a cycloalkyl group wherein 1, 2 or 3 hydrogen atoms of the cycloalkyl group have been replaced by a halogen atom, most preferably fluoro. Particularly preferred, yet non-limiting examples of halocycloalkyl are 1-fluorocyclopropyl and 2,2-difluorocyclopropyl. The term “hydroxycycloalkyl” refers to a cycloalkyl group as defined herein, wherein at least one of the hydrogen atoms of the cycloalkyl group has been replaced by a hydroxy group. Preferably, “hydroxycycloalkyl” refers to a cycloalkyl group wherein 1, 2 or 3 hydrogen atoms of the cycloalkyl group have been replaced by a hydroxy group. A particularly preferred, yet non-limiting example of hydroxycycloalkyl is 1- hydroxycyclopropyl. The term “haloalkylcycloalkyl” refers to a cycloalkyl group as defined herein, wherein at least one of the hydrogen atoms of the cycloalkyl group has been replaced by a haloalkyl group. In some embodiments, “haloalkylcycloalkyl” refers to a cycloalkyl group wherein 1, 2 or 3 hydrogen atoms of the cycloalkyl group have been replaced by a haloalkyl group. Preferably, “haloalkylcycloalkyl” refers to a cycloalkyl group wherein 1 to 2 hydrogen atoms of the cycloalkyl group have been replaced by a haloalkyl group. Particularly preferred, yet non-limiting examples of haloalkylcycloalkyl are 1- (trifluoromethyl)cyclopropyl and 2-(trifluoromethyl)cyclopropyl. The term “haloalkoxy” refers to an alkoxy group as defined herein, wherein at least one of the hydrogen atoms of the alkoxy group has been replaced by a halogen atom, preferably fluoro. Preferably, “haloalkoxy” refers to an alkoxy group wherein 1, 2 or 3 hydrogen atoms of the alkoxy group have been replaced by a halogen atom, most preferably fluoro. Particularly preferred, yet non-limiting examples of haloalkoxy are trifluoromethoxy, difluoromethoxy, 2,2,2-trifluoro-1,1-dimethyl-ethoxy, (1,1,1-trifluoropropan-2-yl)oxy, and 2,2,2-trifluoroethoxy. The term "pharmaceutically acceptable salt" refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, in particular hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein and the like. In addition these salts may be prepared by addition of an inorganic base or an organic base to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like. Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N- ethylpiperidine, piperidine, polyimine resins and the like. The compounds of formula (I) can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereioisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. According to the Cahn-Ingold-Prelog Convention, the asymmetric carbon atom can be of the "R" or "S" configuration. The abbreviation “MAGL” refers to the enzyme monoacylglycerol lipase. The terms “MAGL” and “monoacylglycerol lipase” are used herein interchangeably. The term “treatment” as used herein includes: (1) inhibiting the state, disorder or condition (e.g. arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof); and/or (2) relieving the condition (i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms). The benefit to a patient to be treated is either statistically significant or at least perceptible to the patient or to the physician. However, it will be appreciated that when a medicament is administered to a patient to treat a disease, the outcome may not always be effective treatment. The term “prophylaxis” as used herein includes: preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a mammal and especially a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition. The term “neuroinflammation” as used herein relates to acute and chronic inflammation of the nervous tissue, which is the main tissue component of the two parts of the nervous system; the brain and spinal cord of the central nervous system (CNS), and the branching peripheral nerves of the peripheral nervous system (PNS). Chronic neuroinflammation is associated with neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. Acute neuroinflammation usually follows injury to the central nervous system immediately, e.g., as a result of traumatic brain injury (TBI). The term “traumatic brain injury” (“TBI”, also known as “intracranial injury”), relates to damage to the brain resulting from external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile. The term “neurodegenerative diseases” relates to diseases that are related to the progressive loss of structure or function of neurons, including death of neurons. Examples of neurodegenerative diseases include, but are not limited to, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. The term “mental disorders” (also called mental illnesses or psychiatric disorders) relates to behavioral or mental patterns that may cause suffering or a poor ability to function in life. Such features may be persistent, relapsing and remitting, or occur as a single episode. Examples of mental disorders include, but are not limited to, anxiety and depression. The term “pain” relates to an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Examples of pain include, but are not limited to, nociceptive pain, chronic pain (including idiopathic pain), neuropathic pain including chemotherapy induced neuropathy, phantom pain and phsychogenic pain. A particular example of pain is neuropathic pain, which is caused by damage or disease affecting any part of the nervous system involved in bodily feelings (i.e., the somatosensory system). In one embodiment, “pain” is neuropathic pain resulting from amputation or thoracotomy. In one embodiment, “pain” is chemotherapy induced neuropathy. The term “neurotoxicity” relates to toxicity in the nervous system. It occurs when exposure to natural or artificial toxic substances (neurotoxins) alter the normal activity of the nervous system in such a way as to cause damage to nervous tissue. Examples of neurotoxicity include, but are not limited to, neurotoxicity resulting from exposure to substances used in chemotherapy, radiation treatment, drug therapies, drug abuse, and organ transplants, as well as exposure to heavy metals, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances. The term “cancer” refers to a disease characterized by the presence of a neoplasm or tumor resulting from abnormal uncontrolled growth of cells (such cells being "cancer cells"). As used herein, the term cancer explicitly includes, but is not limited to, hepatocellular carcinoma, colon carcinogenesis and ovarian cancer. The term “mammal” as used herein includes both humans and non-humans and includes but is not limited to humans, non-human primates, canines, felines, murines, bovines, equines, and porcines. In a particularly preferred embodiment, the term “mammal” refers to humans. Compounds of the Invention In a first aspect, the present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: W and Z are each independently selected from CH ₂ and CH ₂ CH ₂ ; Y is selected from CH and N; U is selected from CH and N; V is selected from NH, O, and S; X is selected from NH and O; L is selected from CH2 and O; A is selected from: B is selected from: and a 9-membered fused bicyclic heteroaryl comprising 1-3 heteroatoms selected from N, O, and S, the remaining ring atoms being carbon; R ¹ is selected from hydrogen, halogen, cyano, C ₁ -C ₆ -alkyl, C ₁ -C ₆ -alkoxy, halo- C1-C6-alkyl, halo-C1-C6-alkoxy, C3-C10-cycloalkyl, halo-C3-C10-cycloalkyl, C3-C10-cycloalkyl-C1-C6-alkyl, halo-C1-C6-alkyl-C3-C10-cycloalkyl, C6-C14- aryl, sulfamoyl, a group , and (C ₁ -C ₆ -alkyl) ₂ PO-; R ^1a is selected from C ₁ -C ₆ -alkyl and halo-C ₁ -C ₆ -alkyl; R ² is selected from hydrogen, halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, halo- C1-C6-alkyl, and halo-C1-C6-alkoxy; and R ³ is selected from C ₃ -C ₁₀ -cycloalkyl, hydroxy-C ₃ -C ₁₀ -cycloalkyl, amino-C ₃ -C ₁₀ - cycloalkyl, halo-C3-C10-cycloalkyl, C1-C6-alkyl, halo-C1-C6-alkyl, C1-C6-alkoxy and halo-C1-C6-alkoxy. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: W and Z are each independently selected from CH2 and CH2CH2; Y is selected from CH and N; U is selected from CH and N; V is selected from NH, O, and S; L is selected from CH2 and O; A is selected from: B is selected from: R ¹ is selected from hydrogen, halogen, cyano, C ₁ -C ₆ -alkyl, C ₁ -C ₆ -alkoxy, halo- C1-C6-alkyl, halo-C1-C6-alkoxy, C3-C10-cycloalkyl, halo-C3-C10-cycloalkyl, C3-C10-cycloalkyl-C1-C6-alkyl, halo-C1-C6-alkyl-C3-C10-cycloalkyl, C6-C14- aryl, sulfamoyl, and (C ₁ -C ₆ -alkyl) ₂ PO-; R ² is selected from hydrogen, halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, halo- C1-C6-alkyl, and halo-C1-C6-alkoxy; and R ³ is selected from C ₃ -C ₁₀ -cycloalkyl, hydroxy-C ₃ -C ₁₀ -cycloalkyl, halo-C ₃ -C ₁₀ - cycloalkyl, C ₁ -C ₆ -alkyl, halo-C ₁ -C ₆ -alkyl, C ₁ -C ₆ -alkoxy and halo-C ₁ -C ₆ - alkoxy. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein W and Z are both CH2. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein W and Z are both CH ₂ CH ₂ . In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein Y is CH. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein Y is N. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein W and Z are both CH ₂ ; or W and Z are both CH ₂ CH ₂ ; and Y is selected from CH and N. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein W and Z are both CH2; and Y is CH. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein B is selected from: , , In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein B is selected from: , , , , , , , , , , , , , , , , and . In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein B is selected from: . In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein B is selected from: . In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein B is selected from: In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein B is selected from: In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein B is . In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein B is . In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein B is . In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein L is CH2. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is selected from In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is . In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is . In a one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R ¹ is selected from hydrogen, cyano, C ₁ -C ₆ -alkyl, halo-C ₁ -C ₆ -alkyl, C ₃ -C ₁₀ - cycloalkyl, C3-C10-cycloalkyl-C1-C6-alkyl, halo-C1-C6-alkyl-C3-C10- cycloalkyl, C - 6 C14-aryl, sulfamoyl, a group , and (C1-C6- alkyl) ₂ PO-; R ^1a is selected from C ₁ -C ₆ -alkyl and halo-C ₁ -C ₆ -alkyl; and X is selected from NH and O. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R ¹ is selected from hydrogen, methyl, ethyl, tert-butyl, cyano, CHF2, CF3, 1,1- difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, sulfamoyl, dimethylphosphoryl, phenyl, and (CF3)cyclopropyl; R ^1a is selected from methyl and CF3; and X is selected from NH and O. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R ¹ is selected from halo-C1-C6-alkyl, C3-C10-cycloalkyl, halo-C1-C6-alkyl-C3-C10- cycloalkyl, and a group R ^1a is halo-C ₁ -C ₆ -alkyl; and X is selected from NH and O. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R ¹ is selected from CHF2, CF3, 2,2,2-trifluoroethyl, cyclopropyl, (CF3)cyclopropyl, and a group R ^1a is CF ₃ ; and X is selected from NH and O. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: R ¹ is selected from CF ₃ , cyclopropyl, (CF ₃ )cyclopropyl, and a group ; R ^1a is CF3; and X is selected from NH and O. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ¹ is selected from hydrogen, cyano, C1-C6-alkyl, halo-C1-C6-alkyl, C3-C10-cycloalkyl, C3-C10-cycloalkyl-C1- C ₆ -alkyl, halo-C ₁ -C ₆ -alkyl-C ₃ -C ₁₀ -cycloalkyl, C ₆ -C ₁₄ -aryl, sulfamoyl, and (C ₁ -C ₆ - alkyl) ₂ PO-. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ¹ is selected from hydrogen, methyl, ethyl, tert-butyl, cyano, CHF ₂ , CF ₃ , 1,1-difluoroethyl, 2,2,2- trifluoroethyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, sulfamoyl, dimethylphosphoryl, phenyl, and (CF3)cyclopropyl. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ¹ is selected from halo-C ₁ -C ₆ -alkyl, C ₃ -C ₁₀ -cycloalkyl, and halo-C ₁ -C ₆ -alkyl-C ₃ -C ₁₀ -cycloalkyl. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ¹ is selected from CHF ₂ , CF ₃ , 2,2,2-trifluoroethyl, cyclopropyl, and (CF ₃ )cyclopropyl. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ¹ is selected from CF ₃ , cyclopropyl, and 1-(trifluoromethyl)cyclopropyl. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ¹ is halo-C ₁ -C ₆ -alkyl. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ¹ is CF ₃ . In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ² is selected from hydrogen, C1-C6-alkyl, and halo-C1-C6-alkyl. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ² is selected from hydrogen, methyl, ethyl, and CF3. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ² is selected from hydrogen, methyl, and CF3. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ² is hydrogen. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ³ is selected from C ₃ -C ₁₀ - cycloalkyl, hydroxy-C ₃ -C ₁₀ -cycloalkyl, amino-C ₃ -C ₁₀ -cycloalkyl, and halo-C ₁ -C ₆ -alkyl. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ³ is selected from cyclopropyl, 1-hydroxycyclopropyl, 1-aminocyclopropyl, and CF ₃ . In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ³ is selected from C3-C10- cycloalkyl, hydroxy-C ₃ -C ₁₀ -cycloalkyl, halo-C ₁ -C ₆ -alkyl. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ³ is selected from C ₃ -C ₁₀ -cycloalkyl and halo-C ₁ -C ₆ -alkyl. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ³ is selected from cyclopropyl, hydroxycyclopropyl, and CF ₃ . In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ³ is selected from cyclopropyl and CF3. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ³ is C3-C10- cycloalkyl. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ³ is cyclopropyl. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R ³ is selected CF3. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: W and Z are each independently selected from CH ₂ and CH ₂ CH ₂ ; Y is selected from CH and N; U is selected from CH and N; V is selected from NH, O, and S; X is selected from NH and O; L is selected from CH2 and O; A is selected from B is selected from: R ¹ is selected from hydrogen, cyano, C ₁ -C ₆ -alkyl, halo-C ₁ -C ₆ -alkyl, C ₃ -C ₁₀ - cycloalkyl, C ₃ -C ₁₀ -cycloalkyl-C ₁ -C ₆ -alkyl, halo-C ₁ -C ₆ -alkyl-C ₃ -C ₁₀ - cycloalkyl, C -C -ar 6 14 yl, sulfamoyl, a group , and (C1-C6- alkyl)2PO-; R ^1a is selected from C ₁ -C ₆ -alkyl and halo-C ₁ -C ₆ -alkyl; R ² is selected from hydrogen, C ₁ -C ₆ -alkyl, and halo-C ₁ -C ₆ -alkyl; and R ³ is selected from C3-C10-cycloalkyl, hydroxy-C3-C10-cycloalkyl, amino-C3-C10- cycloalkyl, halo-C ₁ -C ₆ -alkyl. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: W and Z are both CH2; or W and Z are both CH ₂ CH ₂ ; Y is selected from CH and N; X is selected from NH and O; L is CH ₂ ; A is selected from and ; B is selected from: ; R ¹ is selected from halo-C1-C6-alkyl, C3-C10-cycloalkyl, halo-C1-C6-alkyl-C3-C10- cycloalkyl, and a group R ^1a is halo-C ₁ -C ₆ -alkyl; R ² is selected from hydrogen, C1-C6-alkyl, and halo-C1-C6-alkyl; and R ³ is selected from C ₃ -C ₁₀ -cycloalkyl, hydroxy-C ₃ -C ₁₀ -cycloalkyl, halo-C ₁ -C ₆ - alkyl. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: W and Z are both CH ₂ ; or W and Z are both CH ₂ CH ₂ ; Y is selected from CH and N; X is selected from NH and O; L is CH ₂ ; A is selected from B is selected from: , , , , , , , and ; R ¹ is selected from CHF ₂ , CF ₃ , 2,2,2-trifluoroethyl, cyclopropyl, (CF ₃ )cyclopropyl, and a group R ^1a is CF3; R ² is selected from hydrogen, methyl, and CF ₃ ; and R ³ is selected from cyclopropyl, hydroxycyclopropyl, and CF3. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: W and Z are each independently selected from CH ₂ and CH ₂ CH ₂ ; Y is selected from CH and N; U is selected from CH and N; V is selected from NH, O, and S; L is selected from CH2 and O; A is selected from B is selected from: R ¹ is selected from hydrogen, cyano, C1-C6-alkyl, halo-C1-C6-alkyl, C3-C10- cycloalkyl, C3-C10-cycloalkyl-C1-C6-alkyl, halo-C1-C6-alkyl-C3-C10- cycloalkyl, C ₆ -C ₁₄ -aryl, sulfamoyl, and (C ₁ -C ₆ -alkyl) ₂ PO-; R ² is selected from hydrogen, C1-C6-alkyl, and halo-C1-C6-alkyl; and R ³ is selected from C3-C10-cycloalkyl, hydroxy-C3-C10-cycloalkyl, halo-C1-C6- alkyl. In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: W and Z are both CH ₂ ; or W and Z are both CH2CH2; Y is selected from CH and N; L is CH ₂ ; A is selected from B is selected from: ; R ¹ is selected from halo-C1-C6-alkyl, C3-C10-cycloalkyl, and halo-C1-C6-alkyl-C3- C10-cycloalkyl; R ² is selected from hydrogen, C ₁ -C ₆ -alkyl, and halo-C ₁ -C ₆ -alkyl; and R ³ is selected from C3-C10-cycloalkyl, hydroxy-C3-C10-cycloalkyl, halo-C1-C6- alkyl. In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein: W and Z are both CH2; or W and Z are both CH ₂ CH ₂ ; Y is selected from CH and N; L is CH2; A is selected from B is selected from: , , , , , , , and ; R ¹ is selected from CHF ₂ , CF ₃ , 2,2,2-trifluoroethyl, cyclopropyl, and (CF3)cyclopropyl; R ² is selected from hydrogen, methyl, and CF3; and R ³ is selected from cyclopropyl, hydroxycyclopropyl, and CF ₃ . In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is selected from [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1- methyl-5-(trifluoromethyl)pyrazol-4-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1- methyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[2- methyl-4-(trifluoromethyl)pyrazol-3-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[5- (trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1H-pyrazol-5-yl]-2-azaspiro[3.3 ]heptan-2-yl]-[6-[[5- (trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1- methyl-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[[5-[1-(trifluoromethyl)cyclopropyl]-1,3,4-oxadiazol-2-yl ]methyl]-2- azaspiro[3.3]heptan-2-yl]-[6-[3-(trifluoromethyl)-1,2,4-tria zol-1-yl]-2- azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-[1- (trifluoromethyl)cyclopropyl]-1,3,4-oxadiazol-2-yl]methyl]-2 -azaspiro[3.3]heptan-2- yl]methanone; [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]-[6-[[5- (trifluoromethyl)-1H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3 .3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]met hanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[5- (trifluoromethyl)-1H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3 .3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[4- (trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[4- (trifluoromethyl)thiazol-2-yl]oxy-2-azaspiro[3.3]heptan-2-yl ]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1- (trifluoromethyl)pyrazol-4-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]methyl]-2-aza spiro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(trifluoromethyl)- 1,2,4-thiadiazol-5-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]met hanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[3- (trifluoromethyl)-1,2,4-thiadiazol-5-yl]methyl]-2-azaspiro[3 .3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[7-[[3- (trifluoromethyl)isoxazol-5-yl]methyl]-2,7-diazaspiro[3.5]no nan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[2- (trifluoromethyl)thiazol-5-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[5-(trifluoromethyl)-1,2,4-thiadiazol-3-yl]methyl]-2-aza spiro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1,2,4-thiadiazol-3-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]met hanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[5- (trifluoromethyl)-1,2,4-thiadiazol-3-yl]methyl]-2-azaspiro[3 .3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[4- (trifluoromethyl)oxazol-2-yl]methyl]-2-azaspiro[3.3]heptan-2 -yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[7-[[2-methyl-5- (trifluoromethyl)pyrazol-3-yl]methyl]-2,7-diazaspiro[3.5]non an-2-yl]methanone; [7-[[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2,7-di azaspiro[3.5]nonan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[7-[[2-methyl-5- (trifluoromethyl)pyrazol-3-yl]methyl]-2,7-diazaspiro[3.5]non an-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[7-[[2- methyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2,7-diazaspir o[3.5]nonan-2- yl]methanone; [7-[[5-(trifluoromethyl)-1H-pyrazol-3-yl]methyl]-2,7-diazasp iro[3.5]nonan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[7-[[5-(trifluoromethyl)- 1H-pyrazol-3-yl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]methan one; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[7-[[5- (difluoromethyl)thiazol-2-yl]methyl]-2,7-diazaspiro[3.5]nona n-2-yl]methanone; [7-[[5-(difluoromethyl)thiazol-2-yl]methyl]-2,7-diazaspiro[3 .5]nonan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[7-[[5- (difluoromethyl)thiazol-2-yl]methyl]-2,7-diazaspiro[3.5]nona n-2-yl]methanone; [7-[[5-(difluoromethyl)thiazol-2-yl]methyl]-2,7-diazaspiro[3 .5]nonan-2-yl]-[6-[3-(1- hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]-[7-[[5- (trifluoromethyl)-4H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3 .5]nonan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[7-[[5- (trifluoromethyl)-4H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3 .5]nonan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[7-[[5-(trifluoromethyl)- 4H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3.5]nonan-2-yl]meth anone; 1-[[2-[6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]hept ane-2-carbonyl]-2- azaspiro[3.3]heptan-6-yl]methyl]pyrazole-4-carbonitrile; 1-[[2-[6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-aza spiro[3.3]heptane-2- carbonyl]-2-azaspiro[3.3]heptan-6-yl]methyl]pyrazole-4-carbo nitrile; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[4- (trifluoromethyl)imidazol-1-yl]methyl]-2-azaspiro[3.3]heptan -2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4- (trifluoromethyl)imidazol-1-yl]methyl]-2-azaspiro[3.3]heptan -2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[4- (trifluoromethyl)imidazol-1-yl]methyl]-2-azaspiro[3.3]heptan -2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[(3-cyclopropyl-1,2,4- thiadiazol-5-yl)methyl]-2,6-diazaspiro[3.3]heptan-2-yl]metha none; [6-[(3-cyclopropyl-1,2,4-thiadiazol-5-yl)methyl]-2,6-diazasp iro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(3-cyclopropyl-1,2,4-thiadiazol-5-yl)methyl]-2,6-diazasp iro[3.3]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[(3-cyclopropyl-1,2,4-thiadiazol-5-yl)methyl]-2,6-diazasp iro[3.3]heptan-2-yl]-[6-[3-(1- hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [7-[[5-(trifluoromethyl)isothiazol-3-yl]methyl]-2,7-diazaspi ro[3.5]nonan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[7-[[5- (trifluoromethyl)isothiazol-3-yl]methyl]-2,7-diazaspiro[3.5] nonan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[7-[[5- (trifluoromethyl)isothiazol-3-yl]methyl]-2,7-diazaspiro[3.5] nonan-2-yl]methanone; [6-[[5-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2,6-diazasp iro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1H-pyrazol-4-yl]methyl]-2,6-diazaspiro[3.3]heptan-2-yl]metha none; [6-[[4-(trifluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[4- (trifluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4- (trifluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[5-methyl-4-(trifluoromethyl)thiazol-2-yl]methyl]-2,6-di azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-methyl-4- (trifluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[(2-tert-butylthiazol-5-yl)methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(2-tert-butylthiazol-5-yl)methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]-[6-(3-cyclopropyl- 1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]methanone; [6-[(2-tert-butylthiazol-5-yl)methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]-[6-[3-(1- hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[1- methyl-3-(trifluoromethyl)pyrazol-4-yl]oxy-2-azaspiro[3.3]he ptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[4-[1- (trifluoromethyl)cyclopropyl]pyrazol-1-yl]methyl]-2-azaspiro [3.3]heptan-2- yl]methanone; [6-[[1-cyclopropyl-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2 -azaspiro[3.3]heptan-2-yl]- [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-cyclopropyl-3- (trifluoromethyl)pyrazol-4-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[[1-cyclopropyl-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2 -azaspiro[3.3]heptan-2-yl]- [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[7-[[2-methyl-4- (trifluoromethyl)pyrazol-3-yl]methyl]-2,7-diazaspiro[3.5]non an-2-yl]methanone; [7-[[2-methyl-4-(trifluoromethyl)pyrazol-3-yl]methyl]-2,7-di azaspiro[3.5]nonan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[7-[[2-methyl-4- (trifluoromethyl)pyrazol-3-yl]methyl]-2,7-diazaspiro[3.5]non an-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[7-[[2- methyl-4-(trifluoromethyl)pyrazol-3-yl]methyl]-2,7-diazaspir o[3.5]nonan-2- yl]methanone; [6-[[5-methyl-3-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-methyl-3- (trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[5- methyl-3-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[[3-methyl-5-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-methyl-5- (trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[3- methyl-5-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[3-[1- (trifluoromethyl)cyclopropyl]-1,2,4-triazol-1-yl]methyl]-2-a zaspiro[3.3]heptan-2- yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[3-[1- (trifluoromethyl)cyclopropyl]-1,2,4-triazol-1-yl]methyl]-2-a zaspiro[3.3]heptan-2- yl]methanone; [6-[(4-cyclobutylthiadiazol-5-yl)methyl]-2,6-diazaspiro[3.3] heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(4-cyclobutylthiadiazol-5-yl)methyl]-2,6-diazaspiro[3.3] heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[(4-cyclobutylthiadiazol-5-yl)methyl]-2,6-diazaspiro[3.3] heptan-2-yl]-[6-[3-(1- hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [7-[[5-(trifluoromethyl)isoxazol-3-yl]methyl]-2,7-diazaspiro [3.5]nonan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[7-[[5- (trifluoromethyl)isoxazol-3-yl]methyl]-2,7-diazaspiro[3.5]no nan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[7-[[5- (trifluoromethyl)isoxazol-3-yl]methyl]-2,7-diazaspiro[3.5]no nan-2-yl]methanone; [6-[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]methyl]-2,6-d iazaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1,3,4-thiadiazol-2-yl]methyl]-2,6-diazaspiro[3.3]heptan-2-yl ]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]methyl]-2,6-diazaspi ro[3.3]heptan-2- yl]methanone; [6-[[2-methyl-4-(trifluoromethyl)thiazol-5-yl]methyl]-2,6-di azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-methyl-4- (trifluoromethyl)thiazol-5-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[2- methyl-4-(trifluoromethyl)thiazol-5-yl]methyl]-2,6-diazaspir o[3.3]heptan-2- yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-(1- methylpyrazol-4-yl)oxy-2-azaspiro[3.3]heptan-2-yl]methanone; [6-[(4-cyclopropylthiadiazol-5-yl)methyl]-2,6-diazaspiro[3.3 ]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(4-cyclopropylthiadiazol-5-yl)methyl]-2,6-diazaspiro[3.3 ]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[[5-(difluoromethyl)-3-methyl-pyrazol-1-yl]methyl]-2-azas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(difluoromethyl)- 3-methyl-pyrazol-1-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]met hanone; [6-[[5-(difluoromethyl)-3-methyl-pyrazol-1-yl]methyl]-2-azas piro[3.3]heptan-2-yl]-[6-[3- (1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]methanone; [6-[[3-(difluoromethyl)-5-methyl-pyrazol-1-yl]methyl]-2-azas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(difluoromethyl)- 5-methyl-pyrazol-1-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]met hanone; [6-[[3-(difluoromethyl)-5-methyl-pyrazol-1-yl]methyl]-2-azas piro[3.3]heptan-2-yl]-[6-[3- (1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]methanone; [6-[(4-tert-butyloxazol-2-yl)methyl]-2,6-diazaspiro[3.3]hept an-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(4-tert-butyloxazol-2-yl)methyl]-2,6-diazaspiro[3.3]hept an-2-yl]-[6-(3-cyclopropyl- 1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]methanone; [6-[[1-(2,2,2-trifluoroethyl)pyrazol-3-yl]methyl]-2,6-diazas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-(2,2,2- trifluoroethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hepta n-2-yl]methanone; [6-[[5-[1-(trifluoromethyl)cyclopropyl]-1H-1,2,4-triazol-3-y l]methyl]-2- azaspiro[3.3]heptan-2-yl]-[6-[3-(trifluoromethyl)-1,2,4-tria zol-1-yl]-2- azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-[1- (trifluoromethyl)cyclopropyl]-1H-1,2,4-triazol-3-yl]methyl]- 2-azaspiro[3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[4- (trifluoromethyl)triazol-1-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4- (trifluoromethyl)triazol-1-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[4- (trifluoromethyl)thiazol-2-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[[1-(2,2,2-trifluoroethyl)triazol-4-yl]methyl]-2,6-diazas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-(2,2,2- trifluoroethyl)triazol-4-yl]methyl]-2,6-diazaspiro[3.3]hepta n-2-yl]methanone; [6-[[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]methyl]-2,6-diazas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-(2,2,2- trifluoroethyl)pyrazol-4-yl]methyl]-2,6-diazaspiro[3.3]hepta n-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[3- methyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]methyl]-2,6-diaz aspiro[3.3]heptan-2- yl]methanone; [6-[[3-methyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]methyl]-2 ,6-diazaspiro[3.3]heptan-2- yl]-[6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3 .3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-methyl-1-(2,2,2- trifluoroethyl)pyrazol-4-yl]methyl]-2,6-diazaspiro[3.3]hepta n-2-yl]methanone; [6-[[5-methyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]methyl]-2 ,6-diazaspiro[3.3]heptan-2- yl]-[6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3 .3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-methyl-1-(2,2,2- trifluoroethyl)pyrazol-4-yl]methyl]-2,6-diazaspiro[3.3]hepta n-2-yl]methanone; [6-[[1-(trifluoromethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1- (trifluoromethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1H-pyrazol-4-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanone ; [6-[[5-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1-(2,2,2- trifluoroethyl)-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2-az aspiro[3.3]heptan-2- yl]methanone; [6-[[1-(2,2,2-trifluoroethyl)-3-(trifluoromethyl)pyrazol-4-y l]methyl]-2- azaspiro[3.3]heptan-2-yl]-[6-[3-(trifluoromethyl)-1,2,4-tria zol-1-yl]-2- azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-(2,2,2- trifluoroethyl)-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2-az aspiro[3.3]heptan-2- yl]methanone; [6-[(3-cyclopropyl-1H-pyrazol-5-yl)methyl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(3-cyclopropyl-1H-pyrazol-5-yl)methyl]-2-azaspiro[3.3]he ptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[(3-cyclopropyl-1H-pyrazol-5-yl)methyl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[3-(1- hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[3-(trifluoromethyl)- 1,2,4-triazol-1-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methan one; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(trifluoromethyl)- 1,2,4-triazol-1-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methan one; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[3- (trifluoromethyl)-1,2,4-triazol-1-yl]methyl]-2-azaspiro[3.3] heptan-2-yl]methanone; [6-[[4-(trifluoromethyl)-1H-pyrazol-3-yl]methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4-(trifluoromethyl)- 1H-pyrazol-3-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanone ; [6-[(5-cyclopropyl-3-methyl-pyrazol-1-yl)methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(5-cyclopropyl-3-methyl-pyrazol-1-yl)methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[(5-cyclopropyl-3-methyl-pyrazol-1-yl)methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3-(1- hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [6-[(3-cyclopropyl-5-methyl-pyrazol-1-yl)methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(3-cyclopropyl-5-methyl-pyrazol-1-yl)methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[(3-cyclopropyl-5-methyl-pyrazol-1-yl)methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3-(1- hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[2- methyl-5-(trifluoromethyl)triazol-4-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[3- (trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[2-(2,2,2- trifluoroethyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-az aspiro[3.3]heptan-2- yl]methanone; [6-[[2-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)pyrazol-3-y l]methyl]-2- azaspiro[3.3]heptan-2-yl]-[6-[3-(trifluoromethyl)-1,2,4-tria zol-1-yl]-2- azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-(2,2,2- trifluoroethyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-az aspiro[3.3]heptan-2- yl]methanone; [6-[(3-cyclopropylpyrazol-1-yl)methyl]-2-azaspiro[3.3]heptan -2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(3-cyclopropylpyrazol-1-yl)methyl]-2-azaspiro[3.3]heptan -2-yl]-[6-(3-cyclopropyl- 1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[4-(2,2,2- trifluoroethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[2- (trifluoromethyl)imidazol-1-yl]methyl]-2-azaspiro[3.3]heptan -2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[2- (trifluoromethyl)imidazol-1-yl]methyl]-2-azaspiro[3.3]heptan -2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[5- (trifluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[5- (trifluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[5-(trifluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5- (trifluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[3- (trifluoromethyl)isothiazol-5-yl]methyl]-2,6-diazaspiro[3.3] heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[3- (trifluoromethyl)isothiazol-5-yl]methyl]-2,6-diazaspiro[3.3] heptan-2-yl]methanone; [6-[[3-(trifluoromethyl)isothiazol-5-yl]methyl]-2,6-diazaspi ro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3- (trifluoromethyl)isothiazol-5-yl]methyl]-2,6-diazaspiro[3.3] heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[5- (trifluoromethyl)isothiazol-3-yl]methyl]-2,6-diazaspiro[3.3] heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5- (trifluoromethyl)isothiazol-3-yl]methyl]-2,6-diazaspiro[3.3] heptan-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[2-methyl-4- (trifluoromethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[2-methyl-4-(trifluoromethyl)pyrazol-3-yl]methyl]-2,6-di azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-methyl-4- (trifluoromethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[1-methyl-5- (trifluoromethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2,6-di azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-methyl-5- (trifluoromethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[1-methyl-5- (trifluoromethyl)pyrazol-4-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[1-methyl-5-(trifluoromethyl)pyrazol-4-yl]methyl]-2,6-di azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-methyl-5- (trifluoromethyl)pyrazol-4-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2,6-di azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-methyl-5- (trifluoromethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[2-ethyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2,6-dia zaspiro[3.3]heptan-2-yl]-[6- [3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3 ]heptan-2-yl]methanone; [6-[[2-ethyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2,6-dia zaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-ethyl-5- (trifluoromethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[3-(trifluoromethyl)- 1,2,4-oxadiazol-5-yl]methyl]-2,6-diazaspiro[3.3]heptan-2-yl] methanone; [6-[[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl]-2,6-di azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(trifluoromethyl)- 1,2,4-oxadiazol-5-yl]methyl]-2,6-diazaspiro[3.3]heptan-2-yl] methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[7-[[4- (trifluoromethyl)thiazol-2-yl]methyl]-2,7-diazaspiro[3.5]non an-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[7-[[4- (trifluoromethyl)thiazol-2-yl]methyl]-2,7-diazaspiro[3.5]non an-2-yl]methanone; [7-[[4-(trifluoromethyl)thiazol-2-yl]methyl]-2,7-diazaspiro[ 3.5]nonan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[7-[[4- (trifluoromethyl)thiazol-2-yl]methyl]-2,7-diazaspiro[3.5]non an-2-yl]methanone; [6-[[4-(trifluoromethyl)isothiazol-5-yl]methyl]-2,6-diazaspi ro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4- (trifluoromethyl)isothiazol-5-yl]methyl]-2,6-diazaspiro[3.3] heptan-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[1- (trifluoromethyl)pyrazol-4-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[1-(trifluoromethyl)pyrazol-4-yl]methyl]-2,6-diazaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1- (trifluoromethyl)pyrazol-4-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[3-(trifluoromethyl)isoxazol-5-yl]methyl]-2,6-diazaspiro [3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3- (trifluoromethyl)isoxazol-5-yl]methyl]-2,6-diazaspiro[3.3]he ptan-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[5- (difluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-[[5-(difluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3 .3]heptan-2-yl]-[6-[3-(1- hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [6-[[5-(difluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3 .3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5- (difluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-[[5-(trifluoromethyl)isoxazol-3-yl]methyl]-2,6-diazaspiro [3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5- (trifluoromethyl)isoxazol-3-yl]methyl]-2,6-diazaspiro[3.3]he ptan-2-yl]methanone; [6-[[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2,6-di azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-methyl-3- (trifluoromethyl)pyrazol-4-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[2-(2,2,2-trifluoroethyl)tetrazol-5-yl]methyl]-2,6-diaza spiro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-(2,2,2- trifluoroethyl)tetrazol-5-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-[[2-(2,2,2-trifluoroethyl)triazol-4-yl]methyl]-2,6-diazas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-(2,2,2- trifluoroethyl)triazol-4-yl]methyl]-2,6-diazaspiro[3.3]hepta n-2-yl]methanone; [6-[[1-(2,2,2-trifluoroethyl)tetrazol-5-yl]methyl]-2,6-diaza spiro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-(2,2,2- trifluoroethyl)tetrazol-5-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-[(4-tert-butylthiazol-2-yl)methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]-[6-[3-(1- hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [6-[(4-tert-butylthiazol-2-yl)methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(4-tert-butylthiazol-2-yl)methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]-[6-(3-cyclopropyl- 1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[2-(2,2,2- trifluoroethyl)triazol-4-yl]methyl]-2-azaspiro[3.3]heptan-2- yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1-(2,2,2- trifluoroethyl)-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3.3]he ptan-2-yl]methanone; [6-[[3-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol-5-yl]methyl]- 2-azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[3-(2,2,2- trifluoroethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-azaspiro[3.3 ]heptan-2-yl]methanone; [6-[[3-(2,2,2-trifluoroethyl)-1,2,4-oxadiazol-5-yl]methyl]-2 ,6-diazaspiro[3.3]heptan-2-yl]- [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(2,2,2- trifluoroethyl)-1,2,4-oxadiazol-5-yl]methyl]-2,6-diazaspiro[ 3.3]heptan-2-yl]methanone; [6-[(5-tert-butyl-1,3,4-thiadiazol-2-yl)methyl]-2,6-diazaspi ro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(5-tert-butyl-1,3,4-thiadiazol-2-yl)methyl]-2,6-diazaspi ro[3.3]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[(5-tert-butyl-1,3,4-thiadiazol-2-yl)methyl]-2,6-diazaspi ro[3.3]heptan-2-yl]-[6-[3-(1- hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [6-[[2-(trifluoromethyl)oxazol-5-yl]methyl]-2,6-diazaspiro[3 .3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2- (trifluoromethyl)oxazol-5-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-[[2-(trifluoromethyl)oxazol-4-yl]methyl]-2,6-diazaspiro[3 .3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2- (trifluoromethyl)oxazol-4-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[4- (trifluoromethyl)oxazol-2-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-[[4-(trifluoromethyl)oxazol-2-yl]methyl]-2,6-diazaspiro[3 .3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4- (trifluoromethyl)oxazol-2-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-[[3-(trifluoromethyl)isoxazol-4-yl]methyl]-2,6-diazaspiro [3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3- (trifluoromethyl)isoxazol-4-yl]methyl]-2,6-diazaspiro[3.3]he ptan-2-yl]methanone; [6-[[5-(trifluoromethyl)oxazol-4-yl]methyl]-2,6-diazaspiro[3 .3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5- (trifluoromethyl)oxazol-4-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-[[2-(2,2,2-trifluoroethyl)pyrazol-3-yl]methyl]-2,6-diazas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-(2,2,2- trifluoroethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hepta n-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[2- (trifluoromethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[2-(trifluoromethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2- (trifluoromethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[(4-dimethylphosphoryl-2-methyl-pyrazol-3-yl)methyl]-2,6- diazaspiro[3.3]heptan-2- yl]-[6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3 .3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(4- dimethylphosphoryl-2-methyl-pyrazol-3-yl)methyl]-2,6-diazasp iro[3.3]heptan-2- yl]methanone; [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]-[6-[[3- (trifluoromethyl)-1H-1,2,4-triazol-5-yl]methyl]-2,6-diazaspi ro[3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(trifluoromethyl)- 1H-1,2,4-triazol-5-yl]methyl]-2,6-diazaspiro[3.3]heptan-2-yl ]methanone; [6-[[5-(trifluoromethyl)-1H-imidazol-2-yl]methyl]-2,6-diazas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1H-imidazol-2-yl]methyl]-2,6-diazaspiro[3.3]heptan-2-yl]meth anone; [6-[[1-(2,2,2-trifluoroethyl)imidazol-2-yl]methyl]-2,6-diaza spiro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-(2,2,2- trifluoroethyl)imidazol-2-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-[[1-(trifluoromethyl)imidazol-2-yl]methyl]-2,6-diazaspiro [3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1- (trifluoromethyl)imidazol-2-yl]methyl]-2,6-diazaspiro[3.3]he ptan-2-yl]methanone; [6-[[5-(trifluoromethyl)-1H-imidazol-4-yl]methyl]-2,6-diazas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1H-imidazol-4-yl]methyl]-2,6-diazaspiro[3.3]heptan-2-yl]meth anone; [6-[(4-cyclopropylthiazol-2-yl)methyl]-2,6-diazaspiro[3.3]he ptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(4-cyclopropylthiazol-2-yl)methyl]-2,6-diazaspiro[3.3]he ptan-2-yl]-[6-[3-(1- hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [6-[[5-(trifluoromethyl)-1H-pyrazol-3-yl]methyl]-2,6-diazasp iro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1H-pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]heptan-2-yl]metha none; [6-[[1-methyl-5-(trifluoromethyl)triazol-4-yl]methyl]-2,6-di azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-methyl-5- (trifluoromethyl)triazol-4-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(3-phenyl-1,2,4- oxadiazol-5-yl)methyl]-2,6-diazaspiro[3.3]heptan-2-yl]methan one; [6-[1-methyl-5-(trifluoromethyl)pyrazol-4-yl]oxy-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[1-methyl-5- (trifluoromethyl)pyrazol-4-yl]oxy-2-azaspiro[3.3]heptan-2-yl ]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[1-(2,2,2- trifluoroethyl)pyrazol-4-yl]oxy-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[1-(2,2,2- trifluoroethyl)pyrazol-4-yl]oxy-2-azaspiro[3.3]heptan-2-yl]m ethanone; 2-methyl-4-[[2-[6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2 -azaspiro[3.3]heptane-2- carbonyl]-2,6-diazaspiro[3.3]heptan-6-yl]methyl]pyrazole-3-s ulfonamide; 4-[[2-[6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]h eptane-2-carbonyl]-2,6- diazaspiro[3.3]heptan-6-yl]methyl]-2-methyl-pyrazole-3-sulfo namide; [6-[(4-tert-butyl-1H-imidazol-2-yl)methyl]-2,6-diazaspiro[3. 3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(4-tert-butyl-1H-imidazol-2-yl)methyl]-2,6-diazaspiro[3. 3]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1-(2,2,2- trifluoroethyl)triazol-4-yl]methyl]-2-azaspiro[3.3]heptan-2- yl]methanone; [6-[(4-tert-butylisoxazol-3-yl)methyl]-2,6-diazaspiro[3.3]he ptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(4-tert-butylisoxazol-3-yl)methyl]-2,6-diazaspiro[3.3]he ptan-2-yl]-[6-(3-cyclopropyl- 1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-(1H-pyrazol-3- ylmethyl)-2,6-diazaspiro[3.3]heptan-2-yl]methanone; [6-[[3-(1,1-difluoroethyl)-1,2,4-oxadiazol-5-yl]methyl]-2,6- diazaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(1,1- difluoroethyl)-1,2,4-oxadiazol-5-yl]methyl]-2,6-diazaspiro[3 .3]heptan-2-yl]methanone; [6-[[2-(2,2-difluoroethyl)pyrazol-3-yl]methyl]-2,6-diazaspir o[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-(2,2- difluoroethyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]heptan -2-yl]methanone; [6-[[1-(difluoromethyl)pyrazol-4-yl]methyl]-2,6-diazaspiro[3 .3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1- (difluoromethyl)pyrazol-4-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-[[3-(cyclopropylmethyl)-1,2,4-oxadiazol-5-yl]methyl]-2,6- diazaspiro[3.3]heptan-2-yl]- [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]methanone; [6-[[3-(cyclopropylmethyl)-1,2,4-oxadiazol-5-yl]methyl]-2,6- diazaspiro[3.3]heptan-2-yl]- [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(3-tert-butyl-1,2,4-oxadiazol-5-yl)methyl]-2,6-diazaspir o[3.3]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[(3-cyclopropyl-5-methyl-isoxazol-4-yl)methyl]-2,6-diazas piro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(3-cyclopropyl-5-methyl-isoxazol-4-yl)methyl]-2,6-diazas piro[3.3]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[(3-cyclopropyl-5-methyl-isoxazol-4-yl)methyl]-2,6-diazas piro[3.3]heptan-2-yl]-[6-[3- (1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]methanone; [6-[(5-cyclopropyl-2-methyl-pyrazol-3-yl)methyl]-2,6-diazasp iro[3.3]heptan-2-yl]-[6-(3- cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-yl]meth anone; [6-[(5-cyclopropyl-2-methyl-pyrazol-3-yl)methyl]-2,6-diazasp iro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(5-cyclopropyl-2-methyl-pyrazol-3-yl)methyl]-2,6-diazasp iro[3.3]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[(5-cyclobutyl-1H-pyrazol-3-yl)methyl]-2,6-diazaspiro[3.3 ]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(5-cyclobutyl-1H-pyrazol-3-yl)methyl]-2,6-diazaspiro[3.3 ]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[(2-tert-butylpyrazol-3-yl)methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(2-tert-butylpyrazol-3-yl)methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]-[6-(3-cyclopropyl- 1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(2-methylpyrazol-3- yl)methyl]-2,6-diazaspiro[3.3]heptan-2-yl]methanone; [6-[[2-(difluoromethyl)thiazol-5-yl]methyl]-2,6-diazaspiro[3 .3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2- (difluoromethyl)thiazol-5-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; 1-methyl-5-[[2-[6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2 -azaspiro[3.3]heptane-2- carbonyl]-2,6-diazaspiro[3.3]heptan-6-yl]methyl]imidazole-4- carbonitrile; 5-[[2-[6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]h eptane-2-carbonyl]-2,6- diazaspiro[3.3]heptan-6-yl]methyl]-1-methyl-imidazole-4-carb onitrile; 5-[[2-[6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-aza spiro[3.3]heptane-2- carbonyl]-2,6-diazaspiro[3.3]heptan-6-yl]methyl]-1-methyl-im idazole-4-carbonitrile; [6-[(3-cyclopropyl-1H-pyrazol-5-yl)methyl]-2,6-diazaspiro[3. 3]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-(1H-pyrazol-3-ylmethyl)-2,6-diazaspiro[3.3]heptan-2-yl]-[ 6-[3-(trifluoromethyl)-1,2,4- triazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-(pyrazolo[1,5- a]pyridin-3-ylmethyl)-2,6-diazaspiro[3.3]heptan-2-yl]methano ne; [6-[(3-ethyl-1,2,4-thiadiazol-5-yl)methyl]-2,6-diazaspiro[3. 3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(3-ethyl-1,2,4- thiadiazol-5-yl)methyl]-2,6-diazaspiro[3.3]heptan-2-yl]metha none; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[2- methyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1- methyl-4-(trifluoromethyl)pyrazol-3-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[1-(2,2,2- trifluoroethyl)pyrazol-4-yl]methyl]-2-azaspiro[3.3]heptan-2- yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1-(2,2,2- trifluoroethyl)pyrazol-4-yl]methyl]-2-azaspiro[3.3]heptan-2- yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[4- (trifluoromethyl)triazol-2-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[3- (trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[3-(difluoromethyl)- 1H-pyrazol-5-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanone ; [6-[[3-(difluoromethyl)-1H-pyrazol-5-yl]methyl]-2-azaspiro[3 .3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(difluoromethyl)- 1H-pyrazol-5-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanone ; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[3-(trifluoromethyl)- 1H-pyrazol-5-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanone ; [6-[[3-(trifluoromethyl)-1H-pyrazol-5-yl]methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[3- (trifluoromethyl)-1H-pyrazol-5-yl]methyl]-2-azaspiro[3.3]hep tan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(trifluoromethyl)- 1H-pyrazol-5-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanone ; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[(3-cyclopropyl-1H- 1,2,4-triazol-5-yl)methyl]-2-azaspiro[3.3]heptan-2-yl]methan one; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(2,4-dimethylthiazol- 5-yl)methyl]-2,6-diazaspiro[3.3]heptan-2-yl]methanone; [6-[(5-cyclopropyl-1H-1,2,4-triazol-3-yl)methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(5-cyclopropyl-1H- 1,2,4-triazol-3-yl)methyl]-2-azaspiro[3.3]heptan-2-yl]methan one; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(1-methylimidazol-4- yl)methyl]-2,6-diazaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(2-ethyl-4-methyl- 1H-imidazol-5-yl)methyl]-2,6-diazaspiro[3.3]heptan-2-yl]meth anone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(2,4-dimethyloxazol- 5-yl)methyl]-2,6-diazaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(1-methylimidazol-2- yl)methyl]-2,6-diazaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(1,5- dimethylpyrazol-4-yl)methyl]-2,6-diazaspiro[3.3]heptan-2-yl] methanone; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[[5- (trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2,6-diazaspiro[3.3 ]heptan-2-yl]methanone; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[[3- (trifluoromethyl)-1H-pyrazol-5-yl]methyl]-2,6-diazaspiro[3.3 ]heptan-2-yl]methanone; [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]-[6-[[1-(3,3,3- trifluoropropyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[(4- mesylpyrazol-1-yl)methyl]-2-azaspiro[3.3]heptan-2-yl]methano ne; [6-[[4-methyl-5-(trifluoromethyl)-1,2,4-triazol-3-yl]methyl] -2,6-diazaspiro[3.3]heptan-2- yl]-[6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3 .3]heptan-2-yl]methanone; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[7-[[5- (trifluoromethyl)-4H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3 .5]nonan-2-yl]methanone; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[[3-(2,2,2- trifluoroethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-azaspiro[3.3 ]heptan-2-yl]methanone; [7-[[3-(trifluoromethyl)isoxazol-5-yl]methyl]-2,7-diazaspiro [3.5]nonan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(5-cyclopropyl-1H-1,2,4-triazol-3-yl)methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan-2 -yl]methanone; [6-[(1-tert-butylimidazol-2-yl)methyl]-2,6-diazaspiro[3.3]he ptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[[5- (trifluoromethyl)-1H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3 .3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-(3,3,3- trifluoropropyl)pyrazol-3-yl]methyl]-2,6-diazaspiro[3.3]hept an-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4-methyl-5- (trifluoromethyl)-1,2,4-triazol-3-yl]methyl]-2,6-diazaspiro[ 3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]methyl]-2,6-diazaspiro[3.3]heptan-2-yl] methanone; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[[4- (trifluoromethylsulfonimidoyl)pyrazol-1-yl]methyl]-2-azaspir o[3.3]heptan-2- yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[5- (trifluoromethyl)-1,2,4-triazol-1-yl]methyl]-2-azaspiro[3.3] heptan-2-yl]methanone; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[[4- (trifluoromethyl)-1H-imidazol-2-yl]methyl]-2-azaspiro[3.3]he ptan-2-yl]methanone; [6-[(4-mesylpyrazol-1-yl)methyl]-2-azaspiro[3.3]heptan-2-yl] -[6-[3-(trifluoromethyl)- 1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]methanone; [6-[[3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl ]methyl]-2,6- diazaspiro[3.3]heptan-2-yl]-[6-[3-(trifluoromethyl)-1,2,4-tr iazol-1-yl]-2- azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[7-[[3- (trifluoromethyl)isoxazol-5-yl]methyl]-2,7-diazaspiro[3.5]no nan-2-yl]methanone; [6-[3-(1-aminocyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3. 3]heptan-2-yl]-[6-[[1-methyl- 5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-azaspiro[3.3]hepta n-2-yl]methanone; [6-[[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]methyl]-2-a zaspiro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(4-mesylpyrazol-1- yl)methyl]-2-azaspiro[3.3]heptan-2-yl]methanone; [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]-[6-[[5- (trifluoromethyl)-1,2,4-triazol-1-yl]methyl]-2-azaspiro[3.3] heptan-2-yl]methanone; [6-[[3-(difluoromethyl)-1H-pyrazol-5-yl]methyl]-2-azaspiro[3 .3]heptan-2-yl]-[6-[3- (difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan-2 -yl]methanone; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[[5-[1- (trifluoromethyl)cyclopropyl]-1H-1,2,4-triazol-3-yl]methyl]- 2-azaspiro[3.3]heptan-2- yl]methanone; [6-[[1-(2,2,2-trifluoroethyl)triazol-4-yl]methyl]-2-azaspiro [3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[4- (trifluoromethyl)-1H-imidazol-2-yl]methyl]-2-azaspiro[3.3]he ptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-[1- (trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]-2 ,6-diazaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-(2,2,2- trifluoroethyl)-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3.3]he ptan-2-yl]methanone; [6-[[2-(2,2,2-trifluoroethyl)triazol-4-yl]methyl]-2-azaspiro [3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[[4-(trifluoromethylsulfonimidoyl)pyrazol-1-yl]methyl]-2- azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-[(5-cyclopropyl-1H-pyrazol-3-yl)methyl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[3- (difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan-2 -yl]methanone; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[[3- (trifluoromethyl)-1H-pyrazol-5-yl]methyl]-2-azaspiro[3.3]hep tan-2-yl]methanone; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[[4- (trifluoromethyl)-1H-pyrazol-3-yl]methyl]-2-azaspiro[3.3]hep tan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1,2,4-triazol-1-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methan one; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[[5- (trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2-azaspiro[3.3]hep tan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-(2,2,2- trifluoroethyl)triazol-4-yl]methyl]-2-azaspiro[3.3]heptan-2- yl]methanone; [6-[[4-(trifluoromethyl)-1H-imidazol-2-yl]methyl]-2-azaspiro [3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4- (trifluoromethylsulfonimidoyl)pyrazol-1-yl]methyl]-2-azaspir o[3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-(2,2,2- trifluoroethyl)triazol-4-yl]methyl]-2-azaspiro[3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4-(trifluoromethyl)- 1H-imidazol-2-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanon e; [6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[[5-[1- (trifluoromethyl)cyclopropyl]-1H-pyrazol-3-yl]methyl]-2-azas piro[3.3]heptan-2- yl]methanone; [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]-[6-[(4- triflylpyrazol-1-yl)methyl]-2-azaspiro[3.3]heptan-2-yl]metha none; [6-[[5-[1-(trifluoromethyl)cyclopropyl]-1H-pyrazol-3-yl]meth yl]-2-azaspiro[3.3]heptan-2- yl]-[6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3 .3]heptan-2-yl]methanone; [6-[(5-cyclopropylpyrazol-1-yl)methyl]-2-azaspiro[3.3]heptan -2-yl]-[6-(3-cyclopropyl- 1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[(4-triflylpyrazol-1- yl)methyl]-2-azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-[1- (trifluoromethyl)cyclopropyl]-1H-pyrazol-3-yl]methyl]-2-azas piro[3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5- (trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]methyl]-2-aza spiro[3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[7- (trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]methyl]-2-aza spiro[3.3]heptan-2- yl]methanone; and [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[6- (trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]methyl]-2-aza spiro[3.3]heptan-2- yl]methanone. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is selected from [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1- methyl-5-(trifluoromethyl)pyrazol-4-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1- methyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1- methyl-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[[5-[1-(trifluoromethyl)cyclopropyl]-1,3,4-oxadiazol-2-yl ]methyl]-2- azaspiro[3.3]heptan-2-yl]-[6-[3-(trifluoromethyl)-1,2,4-tria zol-1-yl]-2- azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-[1- (trifluoromethyl)cyclopropyl]-1,3,4-oxadiazol-2-yl]methyl]-2 -azaspiro[3.3]heptan-2- yl]methanone; [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]-[6-[[5- (trifluoromethyl)-1H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3 .3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]met hanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1- (trifluoromethyl)pyrazol-4-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]methyl]-2-aza spiro[3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(trifluoromethyl)- 1,2,4-thiadiazol-5-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]met hanone; [7-[[5-(trifluoromethyl)-1H-pyrazol-3-yl]methyl]-2,7-diazasp iro[3.5]nonan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]-[7-[[5- (trifluoromethyl)-4H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3 .5]nonan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[7-[[5-(trifluoromethyl)- 4H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3.5]nonan-2-yl]meth anone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[4- (trifluoromethyl)imidazol-1-yl]methyl]-2-azaspiro[3.3]heptan -2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4- (trifluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[4-[1- (trifluoromethyl)cyclopropyl]pyrazol-1-yl]methyl]-2-azaspiro [3.3]heptan-2- yl]methanone; [6-[[1-cyclopropyl-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2 -azaspiro[3.3]heptan-2-yl]- [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-cyclopropyl-3- (trifluoromethyl)pyrazol-4-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[3-[1- (trifluoromethyl)cyclopropyl]-1,2,4-triazol-1-yl]methyl]-2-a zaspiro[3.3]heptan-2- yl]methanone; [6-[[5-[1-(trifluoromethyl)cyclopropyl]-1H-1,2,4-triazol-3-y l]methyl]-2- azaspiro[3.3]heptan-2-yl]-[6-[3-(trifluoromethyl)-1,2,4-tria zol-1-yl]-2- azaspiro[3.3]heptan-2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-[1- (trifluoromethyl)cyclopropyl]-1H-1,2,4-triazol-3-yl]methyl]- 2-azaspiro[3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4- (trifluoromethyl)triazol-1-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-(trifluoromethyl)- 1H-pyrazol-4-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanone ; [6-[[5-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-(2,2,2- trifluoroethyl)-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2-az aspiro[3.3]heptan-2- yl]methanone; [6-[(3-cyclopropyl-1H-pyrazol-5-yl)methyl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-[(3-cyclopropyl-1H-pyrazol-5-yl)methyl]-2-azaspiro[3.3]he ptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(trifluoromethyl)- 1,2,4-triazol-1-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methan one; [6-[[4-(trifluoromethyl)-1H-pyrazol-3-yl]methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4-(trifluoromethyl)- 1H-pyrazol-3-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanone ; [6-[(5-cyclopropyl-3-methyl-pyrazol-1-yl)methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-[(3-cyclopropyl-5-methyl-pyrazol-1-yl)methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-(3- cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]m ethanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-(2,2,2- trifluoroethyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-az aspiro[3.3]heptan-2- yl]methanone; [6-[[5-(trifluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5- (trifluoromethyl)thiazol-2-yl]methyl]-2,6-diazaspiro[3.3]hep tan-2-yl]methanone; [6-[[3-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol-5-yl]methyl]- 2-azaspiro[3.3]heptan-2-yl]-[6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hept an-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1- methyl-4-(trifluoromethyl)pyrazol-3-yl]methyl]-2-azaspiro[3. 3]heptan-2-yl]methanone; [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1-(2,2,2- trifluoroethyl)pyrazol-4-yl]methyl]-2-azaspiro[3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(difluoromethyl)- 1H-pyrazol-5-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanone ; [6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-y l]-[6-[[3-(trifluoromethyl)- 1H-pyrazol-5-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanone ; [6-[[3-(trifluoromethyl)-1H-pyrazol-5-yl]methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3-(trifluoromethyl)- 1H-pyrazol-5-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanone ; [6-[[2-(2,2,2-trifluoroethyl)triazol-4-yl]methyl]-2-azaspiro [3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[1-(2,2,2- trifluoroethyl)triazol-4-yl]methyl]-2-azaspiro[3.3]heptan-2- yl]methanone; [6-[[4-(trifluoromethyl)-1H-imidazol-2-yl]methyl]-2-azaspiro [3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4- (trifluoromethylsulfonimidoyl)pyrazol-1-yl]methyl]-2-azaspir o[3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[2-(2,2,2- trifluoroethyl)triazol-4-yl]methyl]-2-azaspiro[3.3]heptan-2- yl]methanone; [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[4-(trifluoromethyl)- 1H-imidazol-2-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]methanon e; [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]-[6-[(4- triflylpyrazol-1-yl)methyl]-2-azaspiro[3.3]heptan-2-yl]metha none; and [6-[[5-[1-(trifluoromethyl)cyclopropyl]-1H-pyrazol-3-yl]meth yl]-2-azaspiro[3.3]heptan-2- yl]-[6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3 .3]heptan-2-yl]methanone. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is [6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]h eptan-2-yl]-[6-[[5- (trifluoromethyl)-1H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3 .3]heptan-2-yl]methanone. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5- (trifluoromethyl)-1H-1,2,4-triazol-3-yl]methyl]-2-azaspiro[3 .3]heptan-2-yl]methanone. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is [6-[[5-[1-(trifluoromethyl)cyclopropyl]-1H-1,2,4-triazol-3-y l]methyl]-2- azaspiro[3.3]heptan-2-yl]-[6-[3-(trifluoromethyl)-1,2,4-tria zol-1-yl]-2- azaspiro[3.3]heptan-2-yl]methanone. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[5-[1- (trifluoromethyl)cyclopropyl]-1H-1,2,4-triazol-3-yl]methyl]- 2-azaspiro[3.3]heptan-2- yl]methanone. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is [6-[[5-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is [6-[(3-cyclopropyl-1H-pyrazol-5-yl)methyl]-2-azaspiro[3.3]he ptan-2-yl]-[6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]heptan- 2-yl]methanone. In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is [6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan- 2-yl]-[6-[[3- (trifluoromethyl)-1H-pyrazol-5-yl]methyl]-2-azaspiro[3.3]hep tan-2-yl]methanone. In a particular embodiment, the present invention provides pharmaceutically acceptable salts of the compounds according to formula (I) as described herein. In a further particular embodiment, the present invention provides compounds according to formula (I) as described herein as free bases. In some embodiments, the compounds of formula (I) are isotopically-labeled by having one or more atoms therein replaced by an atom having a different atomic mass or mass number. Such isotopically-labeled (i.e., radiolabeled) compounds of formula (I) are considered to be within the scope of this disclosure. Examples of isotopes that can be incorporated into the compounds of formula (I) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine, and iodine, such as, but not limited to, ² H, ³ H, ¹¹ C, ¹³ C, ¹⁴ C, ¹³ N, ¹⁵ N, ¹⁵ O, ¹⁷ O, ¹⁸ O, ³¹ P, ³² P, ³⁵ S, ¹⁸ F, ³⁶ Cl, ¹²³ I, and ¹²⁵ I, respectively. Certain isotopically-labeled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. ³ H, and carbon-14, i.e., ¹⁴ C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. For example, a compound of formula (I) can be enriched with 1, 2, 5, 10, 25, 50, 75, 90, 95, or 99 percent of a given isotope. Substitution with heavier isotopes such as deuterium, i.e. ² H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements. Substitution with positron emitting isotopes, such as ¹¹ C, ¹⁸ F, ¹⁵ O and ¹³ N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed. Processes of Manufacturing The preparation of compounds of formula (I) of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following general schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those persons skilled in the art. The substituents and indices used in the following description of the processes have the significance given herein, unless indicated to the contrary. If one of the starting materials, intermediates or compounds of formula (I) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps, appropriate protective groups (as described e.g., in “Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wutts, 5th Ed., 2014, John Wiley & Sons, N.Y.) can be introduced before the critical step applying methods well known in the art. Such protective groups can be removed at a later stage of the synthesis using standard methods described in the literature. If starting materials or intermediates contain stereogenic centers, compounds of formula (I) can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art e.g., chiral HPLC, chiral SFC or chiral crystallization. Racemic compounds can e.g., be separated into their antipodes via diastereomeric salts by crystallization with optically pure acids or by separation of the antipodes by specific chromatographic methods using either a chiral adsorbent or a chiral eluent. It is equally possible to separate starting materials and intermediates containing stereogenic centers to afford diastereomerically/enantiomerically enriched starting materials and intermediates. Using such diastereomerically/enantiomerically enriched starting materials and intermediates in the synthesis of compounds of formula (I) will typically lead to the respective diastereomerically/enantiomerically enriched compounds of formula (I). A person skilled in the art will acknowledge that in the synthesis of compounds of formula (I) - insofar not desired otherwise - an “orthogonal protection group strategy” will be applied, allowing the cleavage of several protective groups one at a time each without affecting other protective groups in the molecule. The principle of orthogonal protection is well known in the art and has also been described in literature (e.g. Barany and R. B. Merrifield, J. Am. Chem. Soc.1977, 99, 7363; H. Waldmann et al., Angew. Chem. Int. Ed. Engl.1996, 35, 2056). A person skilled in the art will acknowledge that the sequence of reactions may be varied depending on reactivity and nature of the intermediates. In more detail, the compounds of formula (I) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Also, for reaction conditions described in literature affecting the described reactions see for example: Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, NY.1999). It was found convenient to carry out the reactions in the presence or absence of a solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. The described reactions can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. It is convenient to carry out the described reactions in a temperature range between -78 °C to reflux. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 hours to several days will usually suffice to yield the described intermediates and compounds. The reaction sequence is not limited to the one displayed in the schemes, however, depending on the starting materials and their respective reactivity, the sequence of reaction steps can be freely altered. If starting materials or intermediates are not commercially available or their synthesis not described in literature, they can be prepared in analogy to existing procedures for close analogues or as outlined in the experimental section. The following abbreviations are used in the present text: Ac = acetyl, ACN = acetonitrile , Bn = benzyl, BINAP = (2,2'-bis(diphenylphosphino)- 1,1'-binaphthyl), Boc = tert-butyloxycarbonyl, CAS RN = chemical abstracts registration number, Cbz = benzyloxycarbonyl, CMBP = (Cyanomethylene)tributylphosphorane, Cs2CO3 = cesium carbonate, CO = carbon monoxide, CuCl = copper(I) chloride, CuCN = copper(I) cyanide, CuI = copper(I) iodide, DABCO = 1,4- Diazabicyclo[2.2.2]octane;triethylenediamine, DAST = (diethylamino)sulfur trifluoride, dba = dibenzylideneacetone, DBU = 1,8-diazabicyclo[5,4,0]undec-7-ene, DCE = 1,2- dichloroethane, DCM = dichloromethane, DEAD = diethyl azodicarboxylate, DIAD = diisopropyl azodicarboxylate, DIBAL-H = diisobutyl aluminium hydride, DMAP = 4- dimethylaminopyridine, DME = dimethoxyethane , DMEDA = N,N’- dimethylethylenediamine, DMF = N,N-dimethylformamide, DMF-DMA = N,N- Dimethylformamide dimethyl acetal, DMSO = dimethylsulfoxide, DIPEA (or DIEA) = N,N-diisopropylethylamine, dppf = 1,1 bis(diphenyl phosphino)ferrocene, EDC.HCl = N- (3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, EI = electron impact, ESI = electrospray ionization, EtOAc = ethyl acetate, EtOH = ethanol, h = hour(s), FA = formic acid, H2O = water, H2SO4 = sulfuric acid, HATU = 1-[bis(dimethylamino)methylene]-1H- 1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate, HBTU = O-benzotriazole- N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate, HCl = hydrogen chloride, HOBt = 1-hydroxy-1H-benzotriazole; HPLC = high performance liquid chromatography, iPrMgCl = isopropylmagnesium chloride, I2 = iodine, IPA = 2-propanol, ISP = ion spray positive (mode), ISN = ion spray negative (mode), K ₂ CO ₃ = potassium carbonate, KHCO ₃ = potassium bicarbonate, KI = potassium iodide, KOH = potassium hydroxide, K3PO4 = potassium phosphate tribasic, LiAlH4 or LAH = lithium aluminium hydride, LiHMDS = lithium bis(trimethylsilyl)amide, LiOH = lithium hydroxide, mCPBA = meta- chloroperoxybenzoic acid, MgSO4 = magnesium sulfate, min = minute(s), mL = milliliter, MPLC = medium pressure liquid chromatography, Ms = mesyl, MS = mass spectrum, MTBE = methyl tert-butyl ether, nBuLi = n-butyllithium, NaBH ₃ CN = sodium cyanoborohydride, NaH = sodium hydride, NaHMDS = sodium bis(trimethylsilyl)amide NBS = N-bromosuccinimide, NaHCO3 = sodium hydrogen carbonate, NaNO2 = sodium nitrite, NaBH(OAc) ₃ = sodium triacetoxyborohydride, NaOH = sodium hydroxide, Na2CO3 = sodium carbonate, Na2SO4 = sodium sulfate, Na2S2O3 = sodium thiosulfate, NEt3 = triethylamine (TEA), NH4Cl = ammonium chloride, NMP = N-methyl-2- pyrrolidone, OAc = Acetoxy, T3P = propylphosphonic anhydride, PE = petroleum ether, PG = protective group, Pd-C = palladium on activated carbon, PdCl2(dppf)-CH ₂ Cl ₂ = 1,1'- bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex, Pd2(dba)3 = tris(dibenzylideneacetone)dipalladium(0), Pd(OAc)2 = palladium(II) acetate, Pd(OH) ₂ = palladium hydroxide, Pd(PPh ₃ ) ₄ = tetrakis(triphenylphosphine)palladium(0), PMP = 1,2,2,6,6-Pentamethylpiperidine, PTSA = p-toluenesulfonic acid, R = any group, RP = reverse phase, RT = room temperature, SFC = Supercritical Fluid Chromatography, S-PHOS = 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, TBAI = tetra butyl ammonium iodine, TEA = triethylamine, TFA = trifluoroacetic acid, THF = tetrahydrofuran, TMEDA = N,N,N',N'-tetramethylethylenediamine, Ts = tosyl, TS-TPP = triphenylphospine – polymer bound, ZnCl2 = zinc chloride, prep-TLC = preparative thin layer chromatography. The present compounds of formula I can be prepared by reacting an activated intermediate of formula 2 with the nucleophilic amine 1 by heating in a solvent such as DMF or CH3CN in the presence of a base such as DIPEA. (Scheme 1) Alternatively, the activated intermediate can be formed on the other coupling partner (1) that will make the urea of formula I. Scheme 1 The activated intermediate 2 can be generated transiently in the reaction mixture, or by reacting an amine 3 with a coupling agent such as di(1H-1,2,4-triazol-1-yl)methanone in a solvent such as CH ₂ Cl ₂ in the presence of a base such as DIPEA (Scheme 2). Alternatively, the same strategy as in Schemes 1 and 2 may be used, but with the activated intermediate being constructed initially on amine 1, before coupling with amine 3. Scheme 2 Building blocks of formula 4 where L = CH2, Y = CH can be generated by Suzuki reaction (e.g. (Pd(dppf)Cl ₂ , K ₂ CO ₃ , dioxane/H ₂ O), (X = Br, I) followed by hydrogenation (e.g. Pd/C, H ₂ ). The required boronate intermediate 5 can be generated by reacting a ketone with 4,4,5,5-tetramethyl-2-[(tetramethyl-1,3,2-dioxaborolan-2-yl) methyl]-1,3,2- dioxaborolane (LiTMP, THF, - 78 ºC). (Scheme 3). Where B = N-linked heteroaryl, a Chan-Lam type coupling can be used in place of the Suzuki reaction, followed by the hydrogenation/deprotection. 6 ₅ 7 4 Scheme 3 Alternatively, building blocks of formula 8 with L = CH ₂ and Y = N can be prepared by a reductive amination reaction of aldehyde 9 with suitably protected spirocycle (10) in the presence of a reducing agent such as sodium triacetoxyborohydride or sodium cyanoborohydride, followed by deprotection under standard conditions (e.g. with TsOH when PG = Boc). (Scheme 4) 8 Scheme 4 Alternatively, building blocks of formula 8 with L = CH ₂ and A is Y = N can be prepared by a reductive amination reaction of (hetero)aryl methylhalide (X = Br, I, Cl) 11 with suitably protected spirocycle (10) in the presence of a base such as K ₂ CO ₃ in a solvent such as ACN, followed by deprotection under standard conditions (e.g. with TsOH when PG = Boc). (Scheme 5) 1. alkylation 2. deprotection 1 ¹ ₁₀ Scheme 5 Alternatively, building blocks of formula 12 can be prepared by a Mitsunobu type reaction of heterocycle B (13) with a hydroxyl building block 14 (e.g. using diisopropyl azodicarboxylate and triphenylphosphine, or Tsunoda reagent (cyanomethylenetrimethylphosphorane)), followed by deprotection under standard conditions (e.g. with TsOH when PG = Boc). (Scheme 6) Alternatively, building blocks of formula 12 can be prepared by conversion of hydroxyl building block 14 to a mesylate (e.g. using MsCl, Et3N) followed by an SN2 reaction with the heterocycle B (13) in the presence of a base such as NaH. 1. Mitsunobu-type conditions Scheme 6 Alternatively, building blocks of formula 15 where B is a C-linked heteroaryl and L = - CH2- may be generated using standard heterocyclic synthesis techniques starting from a suitable carboxylic acid or (16) or ester, nitrile (17) or diketone (18) derivative. The nitrile derivatives can be generated from the hydroxyl derivatives (19) via conversion to a mesylate (e.g. using MsCl, Et ₃ N) followed by S _N 2 displacement of the mesylate group with cyanide (e.g. using KCN). The diketone derivatives can be generated from the commercial ester derivatives (20) (Scheme 7). Similar sequences may also be applied where B is a C-linked heteroaryl, L = -CH ₂ - and the spiro-unit is N-linked (i.e. Y = N). Scheme 7 Alternatively, building blocks of formula 21 with L = oxygen, Y = CH and B is (hetero)aryl can be prepared by reacting a suitably protected (spiro)cyclic amine bearing a hydroxyl group (23) with a nucleophilic (hetero)aryl alcohol (22) under Mitsunobu-type conditions (e.g. using Tsunoda reagent, (tributylphosphoranylidene)acetonitrile or PPh ₃ /DIAD), followed by deprotection. (Scheme 8) 1. Mitsunobu type conditions 2. deprotection 2 ² ₂₃ 21 Scheme 8 (Hetero)aryl trifluoromethylcyclopropyl building blocks 24 were not generally available, and were instead generated from halide building block 25 (X = I, Br) via Suzuki reaction with 1-(trifluoromethyl)vinylboronic acid to give 26. Cyclopropanation using diphenyl(methyl)sulfonium tetrafluoroborate and LiHMDS gave the required building block 24. (Scheme 9) This sequence could also be carried out inbetween steps in other synthetic schemes, e.g. for N-linked heteroaryl rings B, these functionalization steps could also be carried out while making building blocks of formula 4, after the Suzuki/hydrogenation sequence, but prior to final deprotection (see Scheme 3). Alternatively the (hetero)aryl trifluoromethylcyclopropyl building blocks could be generated from commercial building blocks via standard heterocyclic synthesis techniques. Scheme 9 Building blocks of formula 3 where A is N-linked heterocyclic can be prepared by reacting nucleophilic heterocycle A (27), with a suitably protected building block 28 (X = leaving group such as OMs, I, Br) in the presence of a base such as Cs2CO3 or NaH, followed by deprotection under standard conditions (e.g. with TsOH when PG = Boc, or palladium catalyzed hydrogenation when PG = Cbz) (Scheme 10). Typically mesylate building blocks 28 were used (X = OMs), which can conveniently be generated from the hydroxyl analog by reacting with MsCl in the presence of a mild base such as Et ₃ N. Scheme 10 Building blocks of formula 3 where A is C-linked heterocyclic can be prepared by standard heterocyclic techniques. For example, building blocks 29 where the A ring is pyrazole can be generated via Knorr-type pyrazole synthesis from hydrazine and a diketone 32. The required diketone can be generated via reaction of a suitable ketone 30 with an acid derivative 31 (X = leaving group, e.g. OAc, OMe) in the presence of a base (e.g. NaH, LDA), followed by deprotection under standard conditions. (Scheme 11) Scheme 11 Alternatively building blocks of formula 3 where A is C-linked could be generated via a metal-catalyzed cross-coupling reaction using suitably functionalized intermediates 33 and 34 (X = reacting groups), where one partner bears an organometallic (e.g. zincate, boronate) typically generated from a halide intermediate such as I or Br, and the other partner bears a halide such as Br or I, followed by deprotection under standard conditions. (Scheme 12) 1. cross-coupling 2. deprotection Scheme 12 In some cases, compounds of formula I could also be generated by combining the steps already described in new combinations e.g. carrying out the coupling in Scheme 1 prior to elaboration of the individual building blocks using the same sequences as described above. In some cases, additional protection and deprotection steps were used before, after or concurrent with the existing synthetic steps. In some cases, compounds of formula I could be further functionalized to give other compounds of formula I. For example, a compound of formula I bearing a (hetero)aryl bromide or iodide can be further functionalized with other groups e.g. small amine, small alkyl using metal catalyzed cross-coupling conditions such as Buchwald or Suzuki reactions. Building blocks 1 can also be subjected to further functionalization reactions (e.g. formation of an amide under standard conditions, alkylation of an alcohol (e.g. using NaH and an alkylating agent in DMF), conversion of boron-containing groups to hydroxyl using alkaline peroxide conditions, oxidation of thioethers to sulfones, or installation of small alkyl groups in place of Br or I groups using metal catalyzed cross-coupling conditions such as Buchwald or Suzuki reactions) before or after deprotection of the nucleophilic amine, to yield other building blocks of formula 1. In some cases, building blocks could be generated from commercially available fragments using standard functional group interconversion techniques (e.g. installation of a halide (e.g. using NIS or NBS), removal of a halide (e.g. under hydrogenation conditions), conversion of halides to other groups e.g. small amine, small alkyl using metal catalyzed cross-coupling conditions such as Buchwald or Suzuki reactions, conversion of iodide to a trifluoromethyl group using a trifluoromethylating reagent (e.g. diphenyl(trifluoromethyl)sulfonium trifluoromethanesulfonate), installation and removal of protecting groups, hydrolysis of an ester to an acid, generation of an amide from an acid and a small amine, conversion of boron-containing groups to hydroxyl using alkaline peroxide conditions, cycloaddition of azidotrimethylsilane with a nitrile to generate a tetrazole, Sandmeyer reaction of an aniline to a bromide, oxidation of thioethers to sulfones, oxidation of thioethers to sulfoximines using PhI(OAc)2 and NH2COONH4, alkylation of hydroxyl or amine groups via S _N 2 reaction or reductive amination, acylation using an activated carbonyl derivative, installation of –SO2Me or –SO2CF3 groups from a iodo- or bromo- building block using literature techniques, installation of small alkyl groups or rings such as cyclopropyl onto heteroaromatic nitrogen using a boronate derivative under Chan-Lam type conditions, or installation of a dimethylphosphoryl group in place of a (hetero)aromatic halide (X = Br, I) group via Pd-catalyzed cross-coupling with dimethylphosphine oxide in the presence of a base such as Et ₃ N). Such techniques may also be used to elaborate commercially available fragments before, after, or intermediate within the synthetic sequences described above. In some cases, building blocks could be generated from commercially available fragments using standard heterocyclic synthesis techniques (e.g. synthesis of pyrazoles, oxadiazoles, imidazoles). In one aspect, the present invention provides a process of manufacturing a compound of formula (I) described herein, or a pharmaceutically acceptable salt thereof, wherein the process is as described in any one of schemes 1 to 12. In one aspect, the present invention provides a process for manufacturing a compound of formula (I) described herein, or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula 2; wherein A and R ³ are as defined herein, with a compound of formula 1; wherein R ¹ , R ² , B, L, W, Y, and Z are as defined herein; by heating in a solvent, such as DMF or CH3CN, in the presence of a base, such as DIPEA, to form said compound of formula (I). In one aspect, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, when manufactured according to any one of the processes described herein. MAGL Inhibitory Activity Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of formula (I) as described herein for inhibiting MAGL in a mammal. In a further aspect, the present invention provides compounds of formula (I) as described herein for use in a method of inhibiting MAGL in a mammal. In a further aspect, the present invention provides the use of compounds of formula (I) as described herein for the preparation of a medicament for inhibiting MAGL in a mammal. In a further aspect, the present invention provides a method for inhibiting MAGL in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein to the mammal. Compounds of formula (I) were profiled for MAGL inhibitory activity by determining the enzymatic activity by following the hydrolysis of the natural substrate 2- arachidonoylglycerol (2-AG) resulting in arachidonic acid, which can be followed by mass spectrometry. This assay is hereinafter abbreviated “2-AG assay”. The 2-AG assay was carried out in 384 well polypropylene assay plates. Compound dilutions were made in 100% DMSO in a polypropylene plate in 3-fold dilution steps to give a final concentration range in the assay from 12.5 µM to 0.8 pM. Compound dilutions were added to MAGL protein in assay buffer (50 mM TRIS, 1 mM EDTA, 0.01% (v/v) Tween-20, 2.5% (v/v) DMSO). After shaking, the plate was incubated for 15 min at RT. To start the reaction, 2- arachidonoylglycerol in assay buffer was added. The final concentrations in the assay was 50 pM for MAGL protein and 8 µM 2-arachidonoylglyerol. After shaking and 30 min incubation at RT, the reaction was quenched by the addition of two assay volumes of acetonitrile containing 4µM of d8-arachidonic acid. The amount of arachidonic acid formed was traced by an online SPE system (Agilent Rapidfire) coupled to a triple quadrupole mass spectrometer. A C18 SPE cartridge (Agilent G9205A) was used in an acetonitrile/water liquid setup. The mass spectrometer was operated in negative electrospray mode following the mass transitions 303.1 259.1 for arachidonic acid and 311.1 267.0 for d8-arachidonic acid. The activity of the compounds was calculated based on the ratio of intensities [arachidonic acid / d8-arachidonic acid]. Table 1 Using the Compounds of the Invention In one aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, as described herein for use as a therapeutically active substance. In a further aspect, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, for use in a method of inhibiting monoacylglycerol lipase in a mammal. In a further aspect, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of diseases or disorders that are associated with monoacylglycerol lipase in a mammal. In a further aspect, the present invention provides a method for the treatment or prophylaxis of diseases or disorders that are associated with monoacylglycerol lipase in a mammal, which method comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as described herein to the mammal. In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as described herein in the preparation of a medicament for the treatment or prophylaxis of diseases or disorders that are associated with monoacylglycerol lipase in a mammal. In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as described herein for the treatment or prophylaxis of diseases or disorders that are associated with monoacylglycerol lipase in a mammal. In one embodiment, said diseases or disorders that are associated with monoacylglycerol lipase are selected from neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease. In one embodiment, said diseases or disorders that are associated with monoacylglycerol lipase are selected from multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome, visceral pain, and inflammatory bowel disease. In one embodiment, said diseases or disorders that are associated with monoacylglycerol lipase are selected from neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, and inflammatory bowel disease in a mammal. In one embodiment, said diseases or disorders that are associated with monoacylglycerol lipase are selected from multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease in a mammal. In one embodiment, said diseases or disorders that are associated with monoacylglycerol lipase are multiple sclerosis. In one embodiment, said diseases or disorders that are associated with monoacylglycerol lipase are selected from neuroinflammation and neurodegenerative diseases. In one embodiment, said diseases or disorders that are associated with monoacylglycerol lipase are neurodegenerative diseases. In one embodiment, said diseases or disorders that are associated with monoacylglycerol lipase are cancer. In one embodiment, said diseases or disorders that are associated with monoacylglycerol lipase are inflammatory bowel disease. In one embodiment, said diseases or disorders that are associated with monoacylglycerol lipase are pain. Pharmaceutical Compositions and Administration In one aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as described herein and a therapeutically inert carrier. In one embodiment, there is provided a pharmaceutical composition according to Example 310 or 311. The compounds of formula (I) and their pharmaceutically acceptable salts can be used as medicaments (e.g. in the form of pharmaceutical preparations). The pharmaceutical preparations can be administered internally, such as orally (e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories). However, the administration can also be effected parentally, such as intramuscularly or intravenously (e.g. in the form of injection solutions). The compounds of formula (I) and their pharmaceutically acceptable salts can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragées and hard gelatin capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragées and hard gelatin capsules. Suitable adjuvants for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi- solid substances and liquid polyols, etc. Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc. Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc. Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi- solid or liquid polyols, etc. Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, viscosity- increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances. The dosage can vary in wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 0.1 mg to 20 mg per kg body weight, preferably about 0.5 mg to 4 mg per kg body weight (e.g. about 300 mg per person), divided into preferably 1-3 individual doses, which can consist, for example, of the same amounts, should be appropriate. It will, however, be clear that the upper limit given herein can be exceeded when this is shown to be indicated. Examples The invention will be more fully understood by reference to the following examples. The claims should not, however, be construed as limited to the scope of the examples. In case the preparative examples are obtained as a mixture of enantiomers, the pure enantiomers can be separated by methods described herein or by methods known to the man skilled in the art, such as e.g., chiral chromatography (e.g., chiral SFC) or crystallization. All reaction examples and intermediates were prepared under an argon atmosphere if not specified otherwise. Example 1 [6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[ 3.3]heptan-2-yl]-[6-[[1-methyl- 5-(trifluoromethyl)pyrazol-4-yl]methyl]-2-azaspiro[3.3]hepta n-2-yl]methanone To a solution of 1-[1-(2-azaspiro[3.3]heptan-6-yl)-1,2,4-triazol-3-yl]cyclopr opanol; 2,2,2- trifluoroacetic acid (A.2) (80 mg, 0.120 mmol ) in N,N-dimethylformamide (0.631 mL) cooled down to 0 °C was added DIPEA (108 mg, 146 µL, 0.838 mmol) followed by addition of bis(1,2,4-triazol-1-yl)methanone (19.6 mg, 0.120 mmol ) after which the reaction mixture was stirred at 0 °C for 30 min.6-[[1-methyl-5-(trifluoromethyl)pyrazol-4-yl]methyl]-2- azaspiro[3.3]heptane; 4-methylbenzenesulfonic acid (B.308) (54.2 mg, 0.126 mmol) was added to the reaction mixture, which was then stirred at 50 °C for 18 h. The crude reaction mixture was directly submitted for reversed-phase HPLC purification to yield the title compound as a colorless gum (38.9 mg). MS (ESI): m/z = 506.3 [M+H] ⁺ In analogy to Example 1, the Examples in the following table were generated via urea coupling, using the respective building blocks A.X and B.X. Example 330 [6-[3-(1-aminocyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3. 3]heptan-2-yl]-[6-[[1-methyl-5- (trifluoromethyl)pyrazol-3-yl]methyl]-2-azaspiro[3.3]heptan- 2-yl]methanone To a solution of N-[1-[1-(2-azaspiro[3.3]heptan-6-yl)-1,2,4-triazol-3-yl]cycl opropyl]carbamic acid tert-butyl ester; acetic acid (A.7) (145 mg, 306 µmol) in N,N-dimethylformamide (1.78 mL) cooled down to 0 °C was added DIPEA (276 mg, 373 µL, 2.14 mmol) followed by addition of bis(1,2,4-triazol-1-yl)methanone (52.7 mg, 321 µmol) after which the reaction mixture was stirred at 0 °C for 30 min. Addition of 6-[[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2- azaspiro[3.3]heptane; 4-methylbenzenesulfonic acid (P.7) (152 mg, 352 µmol ) to the reaction mixture which was then stirred at 50 °C for 18 h. Volatiles were removed in vacuo and the crude residue was dissolved in dichloromethane (1.72 mL) followed by addition of TFA (697 mg, 471 µL, 6.11 mmol) after which the reaction mixture was stirred at RT for 18 h. Volatiles were removed in vacuo, the crude residue was dissolved in DMF and the crude solution was directly submitted for a purification by reversed-phase HPLC to give the title compound as a colorless gum (6.7 mg). MS (ESI): m/z = 505.4 [M+H] ⁺ Step a) N-[1-(1H-1,2,4-triazol-3-yl)cyclopropyl]carbamic acid tert-butyl ester A suspension of N-(1-carbamoylcyclopropyl)carbamic acid tert-butyl ester (CAS: 507264-66-6) (4630 mg, 22.7 mmol) in DMF-DMA (54.0 g, 60.7 mL, 453 mmol) was stirred at 55 °C for 1.5 h. Volatiles were removed in vacuo, the obtained crude residue was dissolved in 1,4-dioxane (80 mL) followed by addition of hydrazine 35% aqueous solution (5.19 g, 5.08 mL, 56.7 mmol) and acetic acid (3.4 g, 3.24 mL, 56.7 mmol) after which the reaction mixture was stirred at 70 °C for 4 h. The reaction mixture was poured into a separating funnel containing EtOAc and sat. aq. NH4Cl solution. After extraction, the organic phase was collected and the aqueous phase was back-extacted with ethyl acetate. The combined organic phases were dried over sodium sulfate and evaporated down to dryness to yield the crude title compound (5.04 g) as a light pink solid, which was used without further purification. MS (ESI): m/z = 169.0 [M-C ₄ H ₈ +H] ⁺ Step b) 6-[3-[1-(tert-butoxycarbonylamino)cyclopropyl]-1,2,4-triazol -1-yl]-2- azaspiro[3.3]heptane-2-carboxylic acid benzyl ester To a solution of 6-methylsulfonyloxy-2-azaspiro[3.3]heptane-2-carboxylic acid benzyl ester (CAS: 2966056-53-9)(7.69 g, 23.6 mmol) in N,N-dimethylformamide (102 mL) was added N- [1-(1H-1,2,4-triazol-3-yl)cyclopropyl]carbamic acid tert-butyl ester (5.05 g, 22.5 mmol ) and cesium carbonate (11.0 g, 33.8 mmol) after which the reaction mixture was stirred at 100 °C for 18 h. Volatiles were removed in vacuo and the crude residue was partitioned between ethyl acetate and water. The organic phase was collected and the aqueous phase was back-extracted with ethyl acetate. The combined organic phases were dried over sodium sulfate and evaporated down to dryness to give 11.5 g of a crude residue which was purified by flash chromatography (eluent heptane/ethyl acetate 5% to 75%) to yield the title compound (4.22 g) as a white solid. MS (ESI): m/z = 454.3 [M+H] ⁺ Note: The title compound was generated along with a regioisomeric side-product. Identity confirmed by NMR analysis. Step c) N-[1-[1-(2-azaspiro[3.3]heptan-6-yl)-1,2,4-triazol-3-yl]cycl opropyl]carbamic acid tert- butyl ester; acetic acid (A.7) A solution of 6-[3-[1-(tert-butoxycarbonylamino)cyclopropyl]-1,2,4-triazol -1-yl]-2- azaspiro[3.3]heptane-2-carboxylic acid benzyl ester (4160 mg, 9.17 mmol) in methanol (30 mL) and AcOH (1.57 mL) in a pressure vessel was placed under argon. The catalyst, 20% Pd(OH)2/C (wet) was added (416 mg), the vessel was exacuated and filled with hydrogen. The reaction was stirred under H ₂ (3 bar) at 40 °C for 18 h, cooled and filtered. The vessel and filter cake were rinsed with methanol. The filtrate was evaporated down to dryness to give 4.3 gg of the crude title compound which was used without further purification (purity approx.80%). MS (ESI) m/z = 320.3 [M+H] ⁺ Synthesis of Building Blocks Example A.1 6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptane; 4-methylbenzenesulfonic acid A solution of tert-butyl 6-(3-cyclopropyl-1H-1,2,4-triazol-1-yl)-2-azaspiro[3.3]hepta ne-2- carboxylate (560mg, 1.84 mmol) in Ethyl acetate (35.6 mL) was treated with 4- methylbenzenesulfonic acid monohydrate (350 mg, 1.84 mmol), at 23 °C. The mixture was heated to 80 °C and stirred for 1 h at this temperature, before being cooled down and evaporated. The residue was treated with DCM and Et2O and left for 16 h at 0 °C. The resulting solid was filtered off and dried, to give the desired product ( 6.0 g, 86% yield) as an off-white solid. MS (ESI): m/z = 205.2 [M+H-Tos] ⁺ Step a): 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester To a solution of tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (CAS RN: 1181816-12-5; 20 g, 94.67 mmol) in MeOH (197.24 mL) was added NaBH4 (7.16 g, 189.34 mmol), at 0 °C under N ₂ . The mixture was stirred for 1 h at 0°C, before being evaporated. The residue was dissolved in saturated aqueous NaHCO3, and the aqueous solution was extracted with DCM. The combined organic layers were dried over MgSO ₄ , filtered, and evaporated, to give the title compound (19 g, 94% yield) as a white solid. MS (ESI): m/z = 158.1 [M+H] ⁺ Step b): tert-butyl 6-methylsulfonyloxy-2-azaspiro[3.3]heptane-2-carboxylate Two batches were conducted in parallel. To a solution of tert-butyl 6-hydroxy-2- azaspiro[3.3]heptane-2-carboxylate (100 g, 468.9 mmol) in DCM (1000 mL) was added TEA (128.0 g,1172.2 mmol), at 23 °C. The reaction mixture was then cooled down to 0 °C, and MsCl (81.49 g, 703.3 mmol) was added dropwise. The mixture was stirred for 16 h at 25 °C, after which both batches were combined together and poured into water (2 L). The organic layer was separated, washed with brine (2x 2000 mL), dried over Na2SO4, filtered, and evaporated, to give the title compound (269 g, quant.) as a crude white solid, which was directly used in the next step. Step c): tert-butyl 6-(3-cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptane- 2-carboxylate To a mixture of 3-cyclopropyl-1H-1,2,4-triazole (112.37 g, 1029.65 mmol) ,tert-butyl 6- methylsulfonyloxy-2-azaspiro[3.3]heptane-2-carboxylate (250.0 g, 858.05 mmol) in ACN (2500 mL) was added cesium carbonate (559.14 g, 1716.09 mmol). The mixture was stirred at 70 °C for 16 h, before being filtered and evaporated. Purification by FC (SiO2; DCM/THF/PE) gave the desired compound (1.10 g, 40.0% yield) as a yellow solid. MS (ESI): m/z = 305.3 [M+H] ⁺ Example A.2 1-[1-(2-azaspiro[3.3]heptan-6-yl)-1,2,4-triazol-3-yl]cyclopr opanol; 2,2,2-trifluoroacetic acid To a solution of 6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3 .3]heptane-2- carboxylic acid tert-butyl ester (6.23 g, 19.06 mmol) in DCM (80 mL) was added TFA (14.68 mL, 190.56 mmol) and the reaction mixture was stirred for 18 h at 23 °C. MS (ESI): m/z = 221.2 [M+H] ⁺ Step a): 3-(1-benzoxycyclopropyl)-1H-1,2,4-triazole A solution of 1-benzoxycyclopropanecarboxamide (CAS RN: 865798-45-4; 9.05 g, 44.96 mmol) in DMF-DMA (120 mL, 899 mmol) was stirred at 90°C for 2.5 h, before being cooled down and evaporated. The residue was dissolved in 1,4-dioxane (110 mL), and treated with hydrazine 35% aqueous solution (8.06 mL, 89.92 mmol) and acetic acid (5.15 mL, 89.92 mmol). The mixture was stirred for 18 h at 90 °C, before being cooled down and evaporated. The residue was dissolved in 150 mL ethyl acetate and poured into a separating funnel containing 100 mL sat. aq. NH4Cl solution. After extraction, the organic phase was collected and the aqueous phase was back-extracted with 150 mL ethyl acetate. The combined organic phases were dried over sodium sulfate and evaporated, to give the crude desired product (10.45 g, 97% yield). MS (ESI): m/z = 216.2 [M+H] ⁺ Step b): 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester To a solution of tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (CAS RN: 1181816-12-5; 20 g, 94.67 mmol) in MeOH (197.24 mL) was added NaBH ₄ (7.16 g, 189.34 mmol), at 0 °C under N2. The mixture was stirred for 1 h at 0°C, before being evaporated. The residue was dissolved in saturated aqueous NaHCO ₃ , and the aqueous solution was extracted with DCM. The combined organic layers were dried over MgSO4, filtered, and evaporated, to give the title compound (19 g, 94% yield) as a white solid. MS (ESI): m/z = 158.1 [M+H] ⁺ Step c): tert-butyl 6-methylsulfonyloxy-2-azaspiro[3.3]heptane-2-carboxylate Two batches were conducted in parallel. To a solution of tert-butyl 6-hydroxy-2- azaspiro[3.3]heptane-2-carboxylate (100 g, 468.9 mmol) in DCM (1000 mL) was added TEA (128.0 g,1172.2 mmol), at 23 °C. The reaction mixture was then cooled down to 0 °C, and MsCl (81.49 g, 703.3 mmol) was added dropwise. The mixture was stirred for 16 h at 25 °C, after which both batches were combined together and poured into water (2 L). The organic layer was separated, washed with brine (2x 2000 mL), dried over Na2SO4, filtered, and evaporated, to give the title compound (269 g, quant.) as a crude white solid, which was directly used in the next step. Step d): tert-butyl 6-[3-(1-benzyloxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro [3.3]heptane-2- carboxylate To a solution of 3-(1-benzyloxycyclopropyl)-1H-1,2,4-triazole (22.0 g, 102.21 mmol) in NMP (220 mL) was added NaH (4.42 g, 183.97 mmol), at 0°C under nitrogen. The resulting yellow solution was stirred at 0 °C for 30 min, before being treated with tert-butyl 6-methylsulfonyloxy- 2-azaspiro[3.3]heptane-2-carboxylate (44.67 g, 153.31 mmol). The mixture was heated to 90 °C, and stirred for 12 h at this temperature. The mixture was cooled down, diluted with 800 mL saturated aqueous NH ₄ CI, and extracted with EtOAc. The combined organic layers were washed with 400 mL brine, dried over Na2SO4, filtered, and evaporated. Purification by FC (SiO2; PE/EtOAc) gave the desired product (22.22 g, 51.95% yield) as a yellow solid. MS (ESI): m/z =411.1 [M+H] ⁺ Step e): 6-[3-(1-hydroxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3 .3]heptane-2-carboxylic acid tert-butyl ester A solution of 6-[3-(1-benzoxycyclopropyl)-1,2,4-triazol-1-yl]-2-azaspiro[3 .3]heptane-2- carboxylic acid tert-butyl ester (40 g, 97.44 mmol) in THF (400 mL) was put under Ar and treated with 5% wet Pd/C (7.0 g, 1488.8 mmol). The mixture was put under H2 atmosphere and was stirred for 5 h at 50 °C and 2 bars, before being put back under Ar atmosphere, filtered, and evaporated. Purification by FC (SiO2; heptane/EtOAc/EtOH) gave the desired product (26.25 g, 85% yield) as a white solid. MS (ESI): m/z = 321.3 [M+H] ⁺ Example A.3 6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptane; 4-methylbenzenesulfonic acid A mixture of tert-butyl 6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptane-2- carboxylate (33.0 g, 99.3 mmol) and p-toluenesulfonic acid (20.52 g, 119.16 mmol) in EtOAc (330 mL) was stirred at 80 °C for 12 h, before being cooled down to 23 °C and evaporated. The residue was treated with water and lyophilized to give the desired compound (40.0 g, 95.43% yield) as a yellow solid. MS (ESI): m/z = 233.1 [M-TsOH+H] ⁺ Step a): tert-butyl 6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]he ptane-2- carboxylate A solution of 3-(trifluoromethyl)-1H-1,2,4-triazole (CAS RN: 60406-75-9; 7.56 g, 55.18 mmol) in DMF (150 mL) was treated with sodium hydride, 60% in oil (2.21 g, 55.18 mmol), at 0 °C under Ar. The mixture was stirred at 20°C for 1 h, and tert-butyl 6-bromo-2- azaspiro[3.3]heptane-2-carboxylate (CAS RN: 2409962-67-8; 12.7 g, 45.99 mmol) in DMF (15mL) was added in one portion. The mixture was stirred at 90 °C for 15 h, cooled down, and diluted with water. The mixture was extracted with EtOAc, and the organic layers were washed with brine, dried over Na ₂ SO ₄ and evaporated. Purification by FC (SiO ₂ ; PE/EtOAc) gave the desired compound (10.7 g, 70.02% yield) as a white solid. MS (ESI): m/z = 277.2 [M-Bu+H] ⁺ Example A.4 6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptane; 2,2,2-trifluoroacetic acid To a solution of 6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptane-2-c arboxylic acid tert-butyl ester (1.80 g, 5.93 mmol) in dichloromethane (21 mL) was added TFA (4.57 mL, 59.33 mmol), at 23 °C. The mixture was stirred for 18 h at this temperature, before being evaporated, to give the desired compound (3.69 g, quant.) as a light yellow viscous oil. MS (ESI): m/z = 204.2 [M+H] ⁺ Step a): tert-butyl 6-(3-cyclopropyl-3-oxo-propanoyl)-2-azaspiro[3.3]heptane-2-c arboxylate To a solution of O2-tert-butyl O6-methyl 2-azaspiro[3.3]heptane-2,6-dicarboxylate (9.0 g, 35.25 mmol) in THF (180 mL) was added cyclopropyl methyl ketone (2.96 g, 35.25 mmol) and NaH (2.37 g, 98.7 mmol) at 20 °C. The mixture was stirred at 60 °C for 12 h, before being cooled down and diluted with water (200 mL). The mixture was extracted with EtOAc, and the combined organic layers were dried over Na2SO4, filtered, and evaporated. Purification by FC (PE/EtOAc) gave the desired product (4.9 g, 45.2% yield) as a yellow solid. Step b): tert-butyl 6-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptane-2-c arboxylate A mixture of tert-butyl 6-(3-cyclopropyl-3-oxo-propanoyl)-2-azaspiro[3.3]heptane-2-c arboxylate (1.0 g, 3.25 mmol), hydrazine hydrate (325.72 mg, 6.51 mmol) in 1,4-dioxane (20 mL) was stirred at 90 °C for 12 h . The reaction was diluted with 50 mL water, and extracted with EtOAc. The combined organic layers were washed with 25 mL brine, dried over Na ₂ SO ₄ , filtered, and evaporated. Purification by FC (SiO2, PE/EtOAc) gave the desired product (930.0 mg, 94.22% yield) as a yellow solid. MS (ESI): m/z = 248.1 [M+H] ⁺ Example A.5 1-[5-(2-azaspiro[3.3]heptan-6-yl)-1H-pyrazol-3-yl]cyclopropa nol; 2,2,2-trifluoroacetic acid To a solution of 6-[3-(1-hydroxycyclopropyl)-1H-pyrazol-5-yl]-2-azaspiro[3.3] heptane-2- carboxylic acid tert-butyl ester (383 mg, 1.2 mmol) in dichloromethane (4 mL) was added TFA (923.81 µL, 11.99 mmol). The mixture was stirred for 18 h at 23 °C, before being evaporated, to give the crude desired product (794 mg, quant.) as a light yellow viscuous oil. MS (ESI): m/z = 220.2 [M+H] ⁺ Step a): 1-[tert-butyl(diphenyl)silyl]oxy-N-methoxy-N-methyl-cyclopro panecarboxamide To a solution of 1-[tert-butyl(diphenyl)silyl]oxycyclopropanecarboxylic acid (CAS RN: 2813270-40-3; 2.70 g, 7.93 mmol) in DMF (30 mL) was added HATU (3.62 g, 9.52 mmol) and DIPEA (3586.94 mg, 27.75 mmol) at 25°C. After 0.1 h, N-methoxymethanamine hydrochloride (927.78 mg, 9.52 mmol) was added at 20°C and the resulting mixture was stirred at 20°C for 12 h. The reaction mixture was diluted with H ₂ O (50 mL) and extracted with EtOAc. The combined organic layers were washed with saturated aqueous NaCl, dried over anhydrous Na2SO4, filtered and evaporated. Purification by FC (SiO2; PE/EtOAc) gave the desired compound (2.8 g, 92.06% yield) as a yellow oil. Step b): 1-[1-[tert-butyl(diphenyl)silyl]oxycyclopropyl]ethanone To a solution of 1-[tert-butyl(diphenyl)silyl]oxy-N-methoxy-N-methyl- cyclopropanecarboxamide (2.80 g, 7.3 mmol) in THF (30 mL) was added methylmagnesium bromide (0.6605 mL, 3M in diethyl ether) at 0°C and the reaction mixture was stirred at 20°C for 2 h. The reaction mixture was quenched by addition of saturated aqueous NH4Cl (50 mL) at 25 °C, and then diluted with H ₂ O (50 mL) and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na ₂ SO ₄ , filtered and evaporated to give the desired compound (2.0 g, 80.93% yield) as a yellow oil. Step c): 1-[1-[tert-butyl(diphenyl)silyl]oxycyclopropyl]ethanone A solution of 2-tert-butoxycarbonyl-2-azaspiro[3.3]heptane-6-carboxylic acid (3000.0 mg, 12.43 mmol) and TEA (1.89 mL, 13.68 mmol) in DCM (30 mL) was treated with 2-methylpropyl carbonochloridate (1.87 g, 13.68 mmol), at 0°C. The mixture was stirred for 12 h at 20 °C, before being treated with water (100 mL) and extracted with EtOAc. The combined organic layers were dried over anhydrous Na ₂ SO ₄ , filtered, and evaporated, to give the desired compound (4.2 g, 98.94% yield) as a yellow oil. Step d): tert-butyl 6-[3-[1-[tert-butyl(diphenyl)silyl]oxycyclopropyl]-3-oxo-pro panoyl]-2- azaspiro[3.3]heptane-2-carboxylate To a solution of 1-[1-[tert-butyl(diphenyl)silyl]oxycyclopropyl]ethanone (2000.0 mg, 5.91 mmol) in THF (40 mL) was added LDA (5.91 mL, 11.82 mmol) (2M in THF) at -78°C under Ar. The mixture was stirred for 1 h at this temperature, before being treated with O2-tert-butyl O6- isobutoxycarbonyl 2-azaspiro[3.3]heptane-2,6-dicarboxylate (4034.03 mg, 11.82 mmol). The mixture was stirred for another hour at this temperature, and allowed to warm up to 0 °C. Water (30 mL) was added, and the mixture was extracted with EtOAc. The combined organic layers were washed with saturated aqueous NaCl, dried over Na ₂ SO ₄ , filtered, and evaporated. Purification by FC (SiO2; PE/EtOAc) gave the desired compound (2.0 g, 60.3% yield) as a yellow oil. MS (ESI): m/z = 484.3 [M+H] ⁺ Step e): tert-butyl 6-[3-(1-hydroxycyclopropyl)-1H-pyrazol-5-yl]-2-azaspiro[3.3] heptane-2- carboxylate To a solution of tert-butyl 6-[3-[1-[tert-butyl(diphenyl)silyl]oxycyclopropyl]-3-oxo-pro panoyl]- 2-azaspiro[3.3]heptane-2-carboxylate (2.0 g, 3.56 mmol) in Ethanol (20 mL) was added hydrazine (228.17 mg, 7.12 mmol), at 20°C. The mixture was stirred for 1 h at 50 °C, before being cooled down and purified by RP-HPLC, to give the desired compound (383.0 mg, 33.51% yield) as a white solid. MS (ESI): m/z = 320.2 [M+H] ⁺ Example A.6 6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hep tane; 2,2,2-trifluoroacetic acid To a solution of 6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hep tane-2-carboxylic acid tert-butyl ester (1690 mg, 5.11 mmol) in dichloromethane (15 mL) was added TFA (5.82 g, 3.93 mL, 51.1 mmol) and the reaction mixture was stirred at RT for 18 h. Volatiles were removed in vacuo to yield 3340mg of the crude title compound as a colorless viscous oil, purity ~50% major contaminant excess of TFA, which was used without further purification. MS (ESI): m/z = 215.2 [M+H] ⁺ Step a) 6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-azaspiro[3.3]hep tane-2-carboxylic acid tert- butyl ester To a solution of 6-methylsulfonyloxy-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (2.7 g, 8.82 mmol) in N,N-dimethylformamide (36 mL) was added 3-(difluoromethyl)-1H-1,2,4- triazole (1000 mg, 8.4 mmol) and cesium carbonate (2.74 g, 8.4 mmol ) after which the reaction mixture was stirred at 90 °C for 18 h. Volatiles were removed in vacuo, the crude residue was partitioned between ethyl acetate and 1 M Na ₂ CO ₃ aqueous solution and the organic phase was collected. The aqueous phase was back-extracted with ethyl acetate. The combined organic phases were dried over sodium sulfate and evaporated down to dryness to yield a residue which was purified by flash chromatography (eluent mixture of heptane and ethyl acetate (10% to 80%)) to give the title compound as a white solid MS (ESI): m/z = 315.2 [M+H] ⁺ Note: Small quanitities of an alternative regioisomer also isolated. Regiochemistry confirmed by NMR analysis. Example B.34 5-(2-azaspiro[3.3]heptan-6-ylmethyl)-3-(trifluoromethyl)-1,2 ,4-thiadiazole; 4- methylbenzenesulfonic acid A mixture of p-toluenesulfonic acid (7.1 g, 41.2 mmol) and tert-butyl 6-[[3-(trifluoromethyl)- 1,2,4-thiadiazol-5-yl]methyl]-2-azaspiro[3.3]heptane-2-carbo xylate (6.51 g, 17.9 mmol) in EtOAc (100 mL) was stirred at 25 °C for 48 h. The reaction mixture was concentrated and crystallized from MTBE to afford the title compound (7753 mg, 12.8 mmol, 71.2% yield) as light yellow solid. MS (ESI): m/z = 264.0 [M-TsOH+H] ⁺ Step a) tert-butyl 6-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene]-2 - azaspiro[3.3]heptane-2-carboxylate A mixture of 2,2,6,6-tetramethylpiperidine (95.9 mL, 568 mmol) in THF (750 mL) was cooled to -30 °C under a N ₂ atmosphere. n-BuLi (227 mL, 568 mmol) was added dropwise, and the reaction mixture was stirred at the same temperature for 30 min. Next, the reaction was cooled to –60 °C, and a solution of 4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborol an-2- yl)methyl]-1,3,2-dioxaborolane (136 g, 506 mmol) in THF (750 mL) was added dropwise. After stirring for 30 min, a solution of tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (100 g, 473 mmol) in THF (300 mL) was added in dropwise at –60 °C. The reaction mixture was allowed to slowly warm up to 25 °C and stirred at 25 °C for 12 h. The mixture was added H ₂ O (8 0mL) slowly and then purified together with an additional batch of equal size by silica gel column (PE/EA=1:0 to 3:1 gradient) to give the title compound (220 g, 656 mmol, approx 69% yield per batch) as a white solid which was confirmed by ¹ H NMR (400 MHz, CHLOROFORM- d) δ = 5.21 - 5.16 (m, 1H), 3.99 - 3.89 (m, 4H), 3.13 - 2.90 (m, 4H), 1.46 - 1.41 (m, 9H), 1.26 - 1.20 ppm (m, 13H). Step b) tert-butyl 6-[[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]methylene]-2- azaspiro[3.3]heptane-2-carboxylate 5-bromo-3-(trifluoromethyl)-1,2,4-thiadiazole (CAS: 1781783-65-0) (7.0 g, 30.0 mmol), tert- butyl 6-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene]-2 -azaspiro[3.3]heptane-2- carboxylate (8.5 g, 25.4 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (4.14 g, 5.07 mmol) and potassium carbonate (7.01 g, 50.7 mmol) were dissolved in 1,4-dioxane (71 mL) and water (12.5 mL). The reaction mixture was heated to 90 °C under argon for 18 h. The reaction mixture was concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine. The extract was dried over sodium sulfate, filtered through a thin layer of silica gel and evaporated. The crude product was purified by flash chromatography (hexane/ethyl acetate 0- 35%) to afford tert-butyl 6-[[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]methylene]-2- azaspiro[3.3]heptane-2-carboxylate (6.5 g, 18.0 mmol, 70.9% yield) as grey solid. MS (ESI): m/z = 360.0 [M-H]-. Step c) tert-butyl 6-[[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]methyl]-2-azas piro[3.3]heptane- 2-carboxylate A mixture of tert-butyl 6-[[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]methylene]-2- azaspiro[3.3]heptane-2-carboxylate (6.5 g, 18.0 mmol) and Pd/C, 10% (574 mg, 0.54 mmol) in EtOAc (120 mL) was stirred in an autoclave for 24 h under 30 bar of H ₂ . Then the reaction mixture was filtered and concentrated to afford the title compound (6.51 g, 17.9 mmol, 99.6% yield) as colorless oil. MS (ESI): m/z = 362.2 [M-H]-. In analogy to Example B.34, the following building blocks were generated using the relevant (hetero)aryl bromide or iodide building block for the Suzuki coupling in Step b. In some cases, alternative salts (e.g. trifluoroacetate, ditosylate, hydrochloride) were also used. To introduce different spiro-ring systems further building block substitutions can be made, for example Example B.353 used tert-butyl 7-oxo-2-azaspiro[3.5]nonane-2-carboxylate (CAS: 1363381-22- 9) in place of tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate in Step a). In some cases the synthesis was planned to include removal of an additional Br group in the hydrogenation step. Example B.32 6-[[4-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]h eptane; 4- methylbenzenesulfonic acid A solution of tert-butyl 6-[[4-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]h eptane-2- carboxylate (675 mg, 1.95 mmol) and p-toluenesulfonic acid (404 mg, 2.35 mmol) in EtOAc (6 mL) was stirred at 80 °C for 12 h. The mixture was concentrated under vacuum to give a residue. To the residue was added deionized water and the mixture was lyophilized to give the title compound (794 mg, 96% yield) as a white solid. MS (ESI): m/z = 246.2 [M-TsOH+H] ⁺ Step a) tert-butyl 6-[[4-(trifluoromethyl)pyrazol-1-yl]methylene]-2-azaspiro[3. 3]heptane-2- carboxylate To a solution of 4-(trifluoromethyl)-1H-pyrazole (2435 mg, 17.9 mmol), tert-butyl 6-[(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)methylene]-2-azaspiro[3. 3]heptane-2-carboxylate (Example B.34, Step a)) (2000 mg, 5.97 mmol) and pyridine (1.45 mL, 17.9 mmol) in DMSO (80 mL) was added copper diacetate (2380 mg, 11.9 mmol) under O2 atmosphere, then stirred at 100 °C for 12 h under O2 (balloon) condition. The aqueous phase was extracted with ethyl acetate (200 mL x 3).The combined organic phase was washed with brine (200 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (eluent of 0 to 30% ethyl acetate/petroleum ether) to give a crude product which was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (640 mg, 31% yield) as a brown solid. MS (ESI): m/z = 288.1 [M-tBu+H] ⁺ Step b) tert-butyl 6-[[4-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]h eptane-2- carboxylate To a solution of tert-butyl 6-[[4-(trifluoromethyl)pyrazol-1-yl]methylene]-2- azaspiro[3.3]heptane-2-carboxylate (690 mg, 2.01 mmol) in EtOAc (7 mL) was added wet Pd/C (230 mg, 0.200 mmol), the mixture was stirred at 25 °C under H ₂ atmosphere (balloon) for 2 h. The mixture was then filtered and the filtrate was concentrated to give the title compound (690 mg, 99% yield) as yellow solid. MS (ESI): m/z = 346.1 [M+H] ⁺ In analogy to Example B.32, the following building blocks were generated using the relevant (hetero)aryl building block for the Chan Lam-type coupling in Step 1. In some cases, alternative salts (e.g. trifluoroacetate, ditosylate, hydrochloride) were also used. Example B.347 5-(2,6-diazaspiro[3.3]heptan-2-ylmethyl)-2-(trifluoromethyl) thiazole; 4- methylbenzenesulfonic acid To a solution of tert-butyl 6-[[2-(trifluoromethyl)thiazol-5-yl]methyl]-2,6- diazaspiro[3.3]heptane-2-carboxylate (2000 mg, 5.5 mmol) in EtOAc (20 mL) was added p- toluenesulfonic acid monohydrate (3141 mg, 16.5 mmol, 3.0 eq) and stirred at 25 °C for 18 h. The reaction mixture was filtered and precipitate washed with ether to give the title compound (2950.0 mg, 4.85 mmol, 88.2% yield) as white solid. MS (ESI): m/z = 264.0 [M – TsOH +H] ⁺ Step a) tert-butyl 6-[[2-(trifluoromethyl)thiazol-5-yl]methyl]-2,6-diazaspiro[3 .3]heptane-2- carboxylate Into a solution of tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate hydrochloride (2526 mg, 10.8 mmol) and 2-(trifluoromethyl)thiazole-5-carbaldehyde (CAS: 903130-38-1) (CAS: 903130- 38-1) (1500 mg, 8.28 mmol) in DCE (30 mL), acetic acid (1.28 mL, 22.4 mmol) was added. After 10 min stirring, sodium triacetoxyborohydride (3686 mg, 17.4 mmol) was added and the resulting mixture was stirred overnight at room temperature. The organic layer was washed with sodium bicarbonate aqueous solution, evaporated and purified by flash chromatography (0-80% acetonitrile in chloroform) to yield the title compound (2000 mg, 5.5 mmol, 66.5% yield) as light brown solid. MS (ESI): m/z = 364.0 [M +H] ⁺ . In analogy to Example B.347, the following building blocks were generated using the relevant building blocks in Step a). Example B.360 3-cyclopropyl-5-(2,6-diazaspiro[3.3]heptan-2-ylmethyl)-1,2,4 -thiadiazole; 4- methylbenzenesulfonic acid To a solution of tert-butyl 6-[(3-cyclopropyl-1,2,4-thiadiazol-5-yl)methyl]-2,6- diazaspiro[3.3]heptane-2-carboxylate (558 mg, 1.66 mmol) in ACN (5 mL) p-toluenesulfonic acid monohydrate (789 mg, 4.15 mmol) was added. The mixture was heated at 50 °C for 10 h. The mixture was cooled, and the precipitated solid was filtered, washed with EtOAc and dried to afford the title compound (844 mg, 1.45 mmol, 83 % yield) as a white solid. MS (ESI): m/z = 237.0 [M+H] ⁺ Step a) tert-butyl 6-[(3-cyclopropyl-1,2,4-thiadiazol-5-yl)methyl]-2,6-diazaspi ro[3.3]heptane-2- carboxylate Into a suspension of 5-(chloromethyl)-3-cyclopropyl-1,2,4-thiadiazole (CAS: 2090447-99-5) (521 mg, 2.98 mmol), tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate hydrochloride (700 mg, 2.98 mmol) in DCM (25 mL), diisopropylethylamine (2.6 mL, 14.9 mmol) was added. The resulting mixture was stirred for 16 h at the room temperature and evaporated. The residue was purified by HPLC to give the title compound (558 mg, 1.66 mmol, 53.4% yield) as a light yellow solid. MS (ESI): m/z = 337.0 [M+H]+ In analogy to Example B.360, the following building blocks were generated using the relevant commercial building blocks in Step b). For 4,6 or 4,5 spiro ring systems, 2,7- diazaspiro[3.5]nonane-2-carboxylic acid tert-butyl ester and tert-butyl 2,6-diazaspiro[3.4]octane- 2-carboxylate respectively can be used in place of 2,6-diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester. In some cases Cs ₂ CO ₃ was used in place of K ₂ CO ₃ . In some cases alternative salts of the commercial spirocyclic amine building block was used (e.g. hydrochloride). Example B.311 6-[[5-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]h eptane; 4- methylbenzenesulfonic acid To a solution of tert-butyl 6-[[5-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]h eptane-2- carboxylate (200 mg, 0.58 mmol) in EtOAc (2 mL) was added p-toluenesulfonic acid (110 mg, 0.64 mmol) and stirred for 12 h at 80 °C. The reaction mixture was filtered and concentrated under reduced pressure to give the title compound (230 mg, 0.55 mmol, 95% yield) as a yellow oil . MS (ESI): m/z = 246.1 [M+H] ⁺ . Step a) tert-butyl 6-[[5-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspiro[3.3]h eptane-2- carboxylate To the mixture of tert-butyl 6-(hydroxymethyl)-2-azaspiro[3.3]heptane-2-carboxylate (CAS: 1363381-93-4) (10.0 g, 44.0 mmol), 5-(trifluoromethyl)-1H-pyrazole (5.99 g, 44.0 mmol), triphenylphosphine (14.4 g, 55.0 mmol) in THF (100 mL) was added diisopropyl azodicarboxylate (10.4 mL, 52.8 mmol) at 0 °C, then the reaction mixture was stirred at 20 °C for 12 h under N ₂ . The reaction mixture was diluted with water 100 mL and extracted with EtOAc 300 mL (100 mL x 3). The combined organic layers were washed with aq. sat. NaCl solution (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by normal phase preparative HPLC to give the title compound (3.7 g, 10.7 mmol, 24.4% yield) as a yellow solid. MS (ESI): m/z = 346.1 [M+H] ⁺ In analogy to Example B.311, the following building block was generated using the relevant commercial building block in Step a). Example B.317 2-(2-azaspiro[3.3]heptan-6-ylmethyl)-5-[1-(trifluoromethyl)c yclopropyl]-1,3,4-oxadiazole; 4-methylbenzenesulfonic acid To a solution of 6-[[5-[1-(trifluoromethyl)cyclopropyl]-1,3,4-oxadiazol-2-yl] methyl]-2- azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (3.22 g, 8.31 mmol ) in isopropyl acetate (163 mL) was added p-toluenesulfonic acid monohydrate (1.9 g, 9.97 mmol). The mixture was stirred at 85 °C for 4 h. The reaction mixture was concentrated in vacuo. Et ₂ O (100 mL) was added (starts to partly crystallize overnight). The mixture was concentrated in vacuo to afford the title compound (4.25 g, 45%) as a white solid. MS (ESI): m/z = 288.0 [M+H] ⁺ Step a) 6-(2-hydrazino-2-keto-ethyl)-2-azaspiro[3.3]heptane-2-carbox ylic acid tert-butyl ester To a solution of 2-(2-tert-butoxycarbonyl-2-azaspiro[3.3]heptan-6-yl)acetic acid (CAS: 1251002-39-7) (2.5 g, 9.79 mmol) in tetrahydrofuran (30 mL) was added CDI (1.75 g, 10.8 mmol). The mixture was stirred at 70 °C for 1.5 h. The RM was cooled to 0 °C, hydrazine monohydrate (1.47 g, 1.42 mL, 29.4 mmol) was added, and the mixture was stirred at RT for 30 min. The reaction mixture was poured into EtOAc/THF 2:1, washed with water and brine, dried over Na ₂ SO ₄ and concentrated in vacuo to afford the title compound (3.85 g, 99%) as a white solid. MS (ESI): m/z = 214.1 [M+H-C4H8] ⁺ Step b) 6-[2-keto-2-[N'-[1-(trifluoromethyl)cyclopropanecarbonyl]hyd razino]ethyl]-2- azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester To a solution of 1-(trifluoromethyl)cyclopropanecarboxylic acid (CAS: 277756-46-4) (1.5 g, 9.72 mmol,) in dichloromethane (30 mL) was added 1-chloro-N,N,2- trimethylpropenylamine (1.56 g, 1.54 mL, 11.7 mmol ). The mixture was stirred at RT for 2 h. This acid chloride solution was added was added dropwise to a solution of 6-(2-hydrazino-2- keto-ethyl)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (3.85 g, 9.72 mmol) and DIEA (2.51 g, 3.4 mL, 19.4 mmol ) in tetrahydrofuran (20 mL) at room temperature. The reaction mixture was stirred at RT for 2 h. The reaction mixture was poured into EtOAc/THF 2:1 and washed with water and brine. The organic layer was dried over Na2SO4 and concentrated in vacuo. The crude material was purified by flash chromatography (silica gel, 80g, 0% to 5% methanol in CH ₂ Cl ₂ ) to the title compound (3.49 g, 84.14%) as white solid. MS (ESI): m/z = 350.1 [M+H-C4H8] ⁺ Step c) 6-[[5-[1-(trifluoromethyl)cyclopropyl]-1,3,4-oxadiazol-2-yl] methyl]-2- azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester To a solution of 6-[2-keto-2-[N'-[1-(trifluoromethyl)cyclopropanecarbonyl]hyd razino]ethyl]-2- azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (3.49 g, 8.61 mmol ) in tetrahydrofuran (40 mL) was added Burgess Reagent (4.1 g, 17.2 mmol). The mixture was stirred at 60 °C for 1 h. The reaction mixture was poured into EtOAc/THF 3:1 and washed with water, and brine. The organic layer was dried over Na2SO4 and concentrated in vacuo. The crude material was purified by flash chromatography (silica gel, 80 g, 0% to 5% methanol in CH2Cl2) to afford 6-[[5-[1- (trifluoromethyl)cyclopropyl]-1,3,4-oxadiazol-2-yl]methyl]-2 -azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (3.22 g, 92%) as white solid. MS (ESI): m/z = 388.2 [M+H] ⁺ . Example P.50 1-(2-Azaspiro[3.3]heptan-6-ylmethyl)-4-(trifluoromethyl)pyri din-2-one; 4- methylbenzenesulfonic acid To a solution of tert-butyl 6-[[4-(trifluoromethyl)triazol-2-yl]methyl]-2-azaspiro[3.3]h eptane-2- carboxylate (2.5 g, 7.2 mmol) in EtOAc (100 mL) was added p-toluenesulfonic acid monohydrate (4.12 g, 21.6 mmol). The reaction mixture was stirred at 25 °C for 18 h, filtered and washed with diethyl ether to afford the title compound (3.63 g, 81% yield) as white powder. MS (ESI): m/z = 247.2 [M+H] ⁺ . Step a) tert-butyl 6-(methylsulfonyloxymethyl)-2-azaspiro[3.3]heptane-2-carboxy late To a stirred solution of tert-butyl 6-(hydroxymethyl)-2-azaspiro[3.3]heptane-2-carboxylate (CAS: 1363381-93-4) (14.9 g, 65.7 mmol) in DCM (299 mL) was added triethylamine (13.7 mL, 98.6 mmol), cooled the reaction mixture to 0 °C followed by dropwise addition of methanesulfonyl chloride (6.1 mL, 78.9 mmol) then reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with water and extracted with DCM, washed with water, brine, dried over anhydrous sodium sulphate and evaporate under reduced pressure to give the title compound (19.8 g, 64.8 mmol, 93.7% yield) as a light yellow solid. MS (ESI): m/z = 250.0 [M-Bu+H] ⁺ . Step b) tert-butyl 6-[[4-(trifluoromethyl)triazol-2-yl]methyl]-2-azaspiro[3.3]h eptane-2- carboxylate To a mixture of 4-(trifluoromethyl)-1H-triazole (2.69 g, 19.7 mmol), lithium bromide (3.41 g, 39.3 mmol) in acetonitrile (300 mL) was added tert-butyl 6-(methylsulfonyloxymethyl)-2- azaspiro[3.3]heptane-2-carboxylate (6.0 g, 19.65 mmol, 1 eq, CAS 2740574-92-7). The reaction mixture was stirred at 50 °C for 18 h, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (silica gel, 220 g, 0% to 100% MTBE in heptane) to afford the title compound (2.5 g, 36% yield) as light yellow solid. MS (ESI): m/z = 247.0 [M+H-Boc] ⁺ . In analogy to Example P.50, the following building block was generated using the relevant commercial building block in Step a). In some cases sodium iodide was used in place of lithium bromide in Step a). Example P.62 6-[[3-(Difluoromethyl)-1H-pyrazol-5-yl]methyl]-2-azaspiro[3. 3]heptane; 2,2,2- trifluoroacetic acid To a solution of tert-butyl 6-[[5-(difluoromethyl)-2-(2-trimethylsilylethoxymethyl)pyraz ol-3- yl]methyl]-2-azaspiro[3.3]heptane-2-carboxylate (6 g, 13.1 mmol) in dichloromethane (40 mL) was added 2,2,2-trifluoroacetic acid (20 mL) at 0 °C. The mixture was stirred at 20 °C for 16 h. The reaction mixture was concentrated in vacuo. The residue was purified by prep-HPLC to afford the title compound (3.94 g, 87% yield) as white solid. MS (ESI): m/z = 228.2 [M+H] ⁺ . Step a) tert-Butyl 6-[[5-(difluoromethyl)-2-(2-trimethylsilylethoxymethyl)pyraz ol-3- yl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate To a mixture of 2-[[5-bromo-3-(difluoromethyl)pyrazol-1-yl]methoxy]ethyl-tri methyl-silane (5.3 g, 16.2 mmol, CAS 2416163-95-4), tert-butyl 6-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)methylene]-2-azaspiro[3.3]heptane-2-carboxylate (5.97 g, 17.8 mmol, CAS 2763647-64-7) and potassium carbonate (4.47 g, 32.4 mmol) in 1,4-dioxane (50 mL) and water (5 mL) was added cyclopenta-2,4-dien-1-yl(diphenyl)phosphane;dichloromethane; dichloropalladium; iron(2+) (1.32 g, 1.62 mmol, 0.1 eq, CAS 95464-05-4) under N2. The mixture was stirred at 100 °C for 2 h under N2 atmosphere. The reaction mixture was poured into water (500 mL). The aqueous phase was extracted with EtOAc (300 mL x 2). The organic phase was washed with brine (600 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=100/1 to 1/1) to afford the title compound (6.1 g, 13.4 mmol, 79% yield) as alight yellow solid. MS (ESI): m/z = 456.3 [M+H] ⁺ . Step b) tert-butyl 6-[[5-(difluoromethyl)-2-(2-trimethylsilylethoxymethyl)pyraz ol-3-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate To a solution of tert-butyl 6-[[5-(difluoromethyl)-2-(2-trimethylsilylethoxymethyl)pyraz ol-3- yl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate (7 g, 15.4 mmol) in EtOAc (100 mL) was added Pd/C 10% (2 g, 4.61 mmol, 0.3 eq) under N ₂ atmosphere. The mixture was stirred at 25 °C for 0.5 h under H2 (15 PSI) atmosphere. The reaction mixture was filtered and concentrated in vacuo to afford tert-butyl 6-[[5-(difluoromethyl)-2-(2-trimethylsilylethoxymethyl)pyraz ol-3- yl]methyl]-2-azaspiro[3.3]heptane-2-carboxylate (6 g, 85% yield) as a colorless oil. Example B.376 6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]oxy-2-azaspiro[3 .3]heptane; 2,2,2- trifluoroacetic acid To a cooled to 0 °C solution of tert-butyl 6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]oxy-2- azaspiro[3.3]heptane-2-carboxylate (315 mg, 0.87 mmol) in DCM (10 mL) trifluoroacetic acid (0.4 mL, 5.23 mmol) was added. The resulting mixture was stirred at 20 °C for 10 h and concentrated. The residue was triturated with Et2O, the precipitated solid was filtered and dried to afford the title compound (254 mg, 0.68 mmol, 75.1 % yield) as a white solid. MS m/z: 262.2 [M-TFA+H] ⁺ Step a) tert-butyl 6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]oxy-2-azaspiro[3 .3]heptane-2- carboxylate A solution of tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate (1000 mg, 4.69 mmol) and 1-methyl-3-(trifluoromethyl)pyrazol-4-ol (CAS: 172834-79-6) (857 mg, 5.16 mmol) in THF (20 mL) was cooled to 0 °C and triphenylphosphine (1599 mg, 6.1 mmol) was added. A solution of diisopropyl azodicarboxylate (1.2 mL, 6.1 mmol) in THF (2mL) was added dropwise under Ar. The mixture was warmed to 20 °C and stirred for 24 h. The mixture was concentrated, the residue was triturated with TBME. A precipitated solid was filtered, the fitrate was concentrated. The residue was purified by FC (silica, DCM in TBME 0-100%) to afford the title compound (315 mg, 0.87 mmol, 18.6 % yield) as a white solid. MS m/z: 306.0 [M-C ₄ H ₈ +H] ⁺ In analogy to Example B.376, the following building block was generated using the relevant commercial building block in Step a). Example B.349 3-(2-azaspiro[3.3]heptan-6-ylmethyl)-5-(trifluoromethyl)-1,2 ,4-thiadiazole;4- methylbenzenesulfonic acid A mixture of tert-butyl 6-[[5-(trifluoromethyl)-1,2,4-thiadiazol-3-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (400 mg, 1.1 mmol) and TsOH (227 mg, 1.32 mmol) in EtOAc (5 mL) was stirred at 80 °C for 3 h. The reaction mixture was concentrated under reduced pressure and lyophilized to afford the title compound (415 mg, 0.95 mmol, 85.3% yield) as a white solid. MS (ESI): m/z = 264.0 [M-TsOH+H] ⁺ Step a) tert-butyl 6-(cyanomethyl)-2-azaspiro[3.3]heptane-2-carboxylate To a solution of tert-butyl 6-(methylsulfonyloxymethyl)-2-azaspiro[3.3]heptane-2-carboxy late (2740574-92-7) (5.0 g, 16.4 mmol) in DMSO (70 mL) was added potassium cyanide (2.45 g, 37.7 mmol) at room temperature. The resulting solution was stirred for 18 h at 80 °C. The reaction was quenched by water (50 mL)and then extracted with TBME (3 x 100 mL). The organic layers were washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuum to give the title compound (3.4 g, 14.4 mmol, 83.6% yield) as white solid. MS (ESI): m/z = 181.0 [M-C4H8+H] ⁺ . Step b) tert-butyl 6-[2-(hydroxyamino)-2-imino-ethyl]-2-azaspiro[3.3]heptane-2- carboxylate To a mixture of hydroxylamine; hydrochloride (2353 mg, 33.9 mmol) in ethanol (25 mL) was added TEA (3426 mg, 33.9 mmol) at 25 °C. After 1 h, tert-butyl 6-(cyanomethyl)-2- azaspiro[3.3]heptane-2-carboxylate (4000 mg, 16.9 mmol) added to the reaction mixture above, then the reaction was stirred at 50 °C for further 12 h. The reaction was concentrated under reduced pressure to give a residue. The residue was dissolved in water (50.0 mL), extracted with ethyl acetate (50.0 mL x 3), the combined extracts were concentrated under reduced pressure to give the title compound (4.5 g, 16.7 mmol, 98.7% yield) as a colorless oil, which was used for next step without further purification. MS (ESI): m/z = 270.1 [M+H] ⁺ Step c) tert-butyl 6-(2-amino-2-imino-ethyl)-2-azaspiro[3.3]heptane-2-carboxyla te; acetic acid To a solution of tert-butyl 6-[2-(hydroxyamino)-2-imino-ethyl]-2-azaspiro[3.3]heptane-2- carboxylate (4.5 g, 16.7 mmol) and Ac ₂ O (2.56 g, 25.1 mmo) in Acetic acid (20 mL) was added Pd/C(wet) (1.2 g) at 25°C. Then the reaction was stirred at 25 °C under H2 atmosphere(H2 balloon) for 12 h. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure to give the crude title compound (5.2 g, 16.6 mmol, 99.3% yield) as a light yellow oil. MS (ESI): m/z = 254.0 [M-AcOH+H] ⁺ Step d) tert-butyl 6-[(5-amino-1,2,4-thiadiazol-3-yl)methyl]-2-azaspiro[3.3]hep tane-2- carboxylate To a solution of tert-butyl 6-(2-amino-2-imino-ethyl)-2-azaspiro[3.3]heptane-2-carboxyla te; acetic acid (3000 mg, 9.57 mmol) in water (30 mL) was added sodium hypochlorite (15.0 mL, 10.5 mmol) dropwise at 0 °C, then the mixture was stirred at 20 °C for 1 h, then diluted with water and extracted with EtOAc (20 mL x 3), the combined organic phase was dried over Na2SO4 and concentrated, the residue was dissolved in Methanol (30 mL), potassium thiocyanate (1023 mg, 10.5 mmol) was added at 0°C, then the solution was stirred at 20 °C for 11 h. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column on silica (ethyl acetate:petroleum ether 0-80%) and concentrated under reduced pressure to give the title compound (1400 mg, 4.51 mmol, 47.1% yield) as a brown solid. MS (ESI): m/z = 311.0 [M+H] ⁺ Step e) tert-butyl 6-[(5-iodo-1,2,4-thiadiazol-3-yl)methyl]-2-azaspiro[3.3]hept ane-2-carboxylate To a mixture of tert-butyl 6-[(5-amino-1,2,4-thiadiazol-3-yl)methyl]-2-azaspiro[3.3]hep tane-2- carboxylate (1400 mg, 4.51 mmoland CuI (1718 mg, 9.02 mmol) in MeCN (50 mL) was added a solution of tert-butyl nitrite (930 mg, 9.02 mmol, 2.0 eq) in MeCN (5 mL) at 25 °C, then the reaction was stirred at 70 °C under N ₂ atmosphere for 12 h. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column on silica (ethyl acetate:petroleum ether 0-40%) and concentrated under reduced pressure to give the title compound (900 mg, 2.14 mmol, 47.4% yield) as a yellow solid. MS (ESI): m/z = 421.9 [M+H] ⁺ Step f) tert-butyl 6-[[5-(trifluoromethyl)-1,2,4-thiadiazol-3-yl]methyl]-2-azas piro[3.3]heptane- 2-carboxylate A mixture of tert-butyl 6-[(5-iodo-1,2,4-thiadiazol-3-yl)methyl]-2-azaspiro[3.3]hept ane-2- carboxylate (890 mg, 2.11 mmol), Diphenyl(trifluoromethyl)sulfonium trifluoromethanesulfonate (1025 mg, 2.54 mmol) and Cu (1207 mg, 6.34 mmol) in DMF (8 mL) was stirred at 60 °C under N ₂ atmosphere for 12 h. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by reverse flash (FA condition; MeCN:H2O = 0-70%) and lyophilized to afford a residue. This residue was purified by column on silica (ethyl acetate:petroleum ether 0-30%) and concentrated under reduced pressure to give the title compound (400 mg, 1.1 mmol, 52.1% yield) as a colorless oil. MS (ESI): m/z = 307.9 [M-C4H8+H] ⁺ Example B.377 6-[[4-[1-(trifluoromethyl)cyclopropyl]pyrazol-1-yl]methyl]-2 -azaspiro[3.3]heptane; 4- methylbenzenesulfonic acid A solution of tert-butyl 6-[[4-[1-(trifluoromethyl)cyclopropyl]pyrazol-1-yl]methyl]-2 - azaspiro[3.3]heptane-2-carboxylate (400 mg, 1.04 mmol) and p-toluenesulfonic acid (214 mg, 1.25 mmol) in EtOAc (8 mL) was stirred at 80 °C for 12 h. The reaction mixture was concentrated and lyophilized to give the title compound (467 mg, 1.02 mmol, 91 % yield) as a light brown solid. MS (ESI): m/z = 286.2 [M+H] ⁺ Step a) tert-butyl 6-[(4-bromopyrazol-1-yl)methylene]-2-azaspiro[3.3]heptane-2- carboxylate To a solution of 4-bromopyrazole (2000 mg, 13.6 mmol) in DCE (40 mL) were added tert-butyl 6-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene]-2 -azaspiro[3.3]heptane-2- carboxylate (6840 mg, 20.4 mmol), pyridine (2153 mg, 27.2 mmol), boric acid (841 mg, 13.6 mmol) and Cu(OAc)2 (3670 mg, 18.4 mmol). The mixture was stirred at 70 °C for 12 h under O2. The reaction mixture was purified by prep-HPLC and lyophilized. The residue was triturated in petroleum ether (10 mL) and stirred for 10 min. The solid was collected by filtration to give the title compound (2867 mg, 8.09 mmol, 59% yield) as an off-white solid. MS (ESI): m/z = 298.1 [M+H] ⁺ Step b) tert-butyl 6-[(4-bromopyrazol-1-yl)methyl]-2-azaspiro[3.3]heptane-2-car boxylate To a solution of tert-butyl 6-[(4-bromopyrazol-1-yl)methylene]-2-azaspiro[3.3]heptane-2- carboxylate (2300 mg, 6.49 mmol) in EtOAc (25 mL) was added PtO2 (920 mg, 4.05 mmol) at 20 °C under N ₂ , then the mixture was stirred at 20 °C under H ₂ atmosphere (balloon) for 1 h. The precipitate was filtered off and the filtrate was dried in vacuo. The residue was purified over column chromatography (hexane/EtOAc, 1:1) to give the title compound (2200 mg, 6.18 mmol, 95% yield) as a light yellow solid. MS (ESI): m/z = 302.0 [M-C ₄ H ₈ +H] ⁺ Step c) tert-butyl 6-[[4-[1-(trifluoromethyl)vinyl]pyrazol-1-yl]methyl]-2-azasp iro[3.3]heptane- 2-carboxylate To a solution of tert-butyl 6-[(4-bromopyrazol-1-yl)methyl]-2-azaspiro[3.3]heptane-2- carboxylate (1700 mg, 4.77 mmol) in 1,4-Dioxane (20 mL) and water (4 mL) was added 1- (trifluoromethyl)vinylboronic acid hexylene glycol ester (1270 mg, 5.73 mmol), K2CO3 (1980 mg, 14.3 mmol) and [1,1'-BIS(DIPHENYLPHOSPHINO)FERROCENE]PALLADIUM (II) CHLORIDE (390 mg, 0.48 mmol) under N ₂ . The mixture was stirred at 80 °C for 12 h under N ₂ atmosphere. The precipitate was filtered off and the filtrate was dried in vacuo. The residue was purified over column chromatography (PE/EA, 0-60%). The reaction mixture was purified by prep-HPLC, and lyophilized to give the title compound (1134.0 mg, 3.05 mmol, 64 % yield) as light brown solid. MS (ESI): m/z = 372.1 [M+H] ⁺ Step d) tert-butyl 6-[[4-[1-(trifluoromethyl)cyclopropyl]pyrazol-1-yl]methyl]-2 - azaspiro[3.3]heptane-2-carboxylate To a solution of tert-butyl 6-[[4-[1-(trifluoromethyl)vinyl]pyrazol-1-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (1000 mg, 2.69 mmol) in THF (20 mL) was added diphenyl(methyl)sulfonium tetrafluoroborate (1008 mg, 3.5 mmol).The suspension was cooled to 0 °C and NaHMDS/THF (1 M) (10.8 mL, 10.8 mmol) was added dropwise. The reaction mixture was warmed to 20 °C for and stirred for 12 h. The reaction mixture was purified by prep-HPLC and lyophilized to give the title compound (432 mg, 1.12 mmol, 42 % yield) as light yellow solid. MS (ESI): m/z = 386.1 [M+H] ⁺ In analogy to Example B.377, the following building block was generated using the relevant commercial building blocks. Example B.379 6-[[1-cyclopropyl-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2- azaspiro[3.3]heptane; 4- methylbenzenesulfonic acid To the mixture of tert-butyl 6-[[1-cyclopropyl-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (790 mg, 2.05 mmol) in EtOAc (8 mL) was added p- toluenesulfonic acid (388 mg, 2.25 mmol) at 25 °C, then the reaction mixture was stirred at 80 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue.20 mL deionized water and 2 mL ACN was added to the residue, which was then lyophilized to give the title compound (811 mg, 1.77 mmol, 85% yield) as a yellow oil. MS (ESI): m/z = 286.1 [M-TsOH+H] ⁺ Step a) tert-butyl 6-[[5-(trifluoromethyl)-1H-pyrazol-4-yl]methylene]-2-azaspir o[3.3]heptane-2- carboxylate To the solution of tert-butyl 6-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene]-2 - azaspiro[3.3]heptane-2-carboxylate (5009 mg, 14.9 mmol), 4-bromo-5-(trifluoromethyl)-1H- pyrazole (2920 mg, 13.6 mmol) in 1,4-dioxane (73 mL), water (14.6 mL) was added potassium carbonate (3750 mg, 27.2 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (554 mg, 0.68 mmol) at 20 °C, then the reaction was stirred at 100 °C for 12 h under N2. The reaction mixture was filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (eluent of 0-40% ethyl acetate/petroleum ether) to give a crude product which was further purified by flash silica gel chromatography (eluent of 0-40% ethyl acetate/petroleum ether) to give the title compound (790 mg, 2.3 mmol, 17 % yield) as a yellow oil. MS (ESI): m/z = 288.0 [M-C ₄ H ₈ +H] ⁺ . Step b) tert-butyl 6-[[1-cyclopropyl-3-(trifluoromethyl)pyrazol-4-yl]methylene] -2- azaspiro[3.3]heptane-2-carboxylate To a mixture of tert-butyl 6-[[5-(trifluoromethyl)-1H-pyrazol-4-yl]methylene]-2- azaspiro[3.3]heptane-2-carboxylate (600 mg, 1.75 mmol), cyclopropylboronic acid (600 mg, 6.99 mmol) in DCE (6 mL) was added pyridine (0.42 mL, 5.24 mmol), boric acid (108 mg, 1.75 mmol), copper diacetate (698 mg, 3.5 mmol) at 20 °C, then the reaction mixture was stirred at 100 °C for 16 h under O ₂ (balloon). The reaction mixture was filtered and then diluted with water 50 mL and extracted with EtOAc 150 mL (50 mL x 3). The combined organic layers were washed with brine (40 mL) dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by silica gel chromatography (0-28% ethyl acetate/petroleum ether) to give the title compound (350 mg, 0.91 mmol, 52 %) as a colorless oil. MS (ESI): m/z = 328.0 [M-C4H8+H] ⁺ . Step c) tert-butyl 6-[[1-cyclopropyl-3-(trifluoromethyl)pyrazol-4-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate To the mixture of tert-butyl 6-[[1-cyclopropyl-3-(trifluoromethyl)pyrazol-4-yl]methylene] -2- azaspiro[3.3]heptane-2-carboxylate (720 mg, 1.88 mmol) in EtOAc (15 mL) was added Pd/C (wet, 216 mg, 10 %) at 25 °C, then the reaction mixture was stirred at 25 °C for 0.5 h under H ₂ (15 Psi). The reaction mixture was filtered and the filter liquor was concentrated under reduced pressure to give the title compound (640 mg, 1.66 mmol, 88.4% yield) as a colorless oil. MS (ESI): m/z = 330.0 [M-C ₄ H ₈ +H] ⁺ . Example B.381 6-[[5-methyl-3-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azasp iro[3.3]heptane; 4- methylbenzenesulfonic acid A mixture of tert-butyl 6-[[5-methyl-3-(trifluoromethyl)pyrazol-1-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (3.8 g, 10.57 mmol, 1.0 eq) and p-toluenesulfonic acid (4.55 g, 26.43 mmol, 2.5 eq) in EtOAc (70 mL) was stirred at 25 °C for 24 h. Then the reaction mixture was concentrated and crystallized from MTBE to give 4-methylbenzenesulfonic acid;6- [[5-methyl-3-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azaspir o[3.3]heptane (3940 mg, 9.13 mmol, 86 % yield) as white solid. MS (ESI): m/z = 260.2 [M+H] ⁺ Step a) tert-butyl 6-[[5-methyl-3-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azasp iro[3.3]heptane- 2-carboxylate To a solution of tert-butyl 6-(hydroxymethyl)-2-azaspiro[3.3]heptane-2-carboxylate (1000 mg, 4.4 mmol) in toluene (20 mL) was added 3-methyl-5-(trifluoromethyl)-1H-pyrazole (CAS: 10010-93-2) (660 mg, 4.4 mmol), and (Cyanomethylene)tributylphosphorane (1590 mg, 6.6 mmol). The reaction mixture was stirred at 100 °C for 12 h under N2 atmosphere. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC and lyophilized to give the title compound (485 mg, 1.35 mmol, 31% yield) as dark brown powder. MS (ESI): m/z = 304.0 [M+H] ⁺ Note: Regioisomer tert-butyl 6-[[3-methyl-5-(trifluoromethyl)pyrazol-1-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (735 mg, 2.05 mmol, 46.5 % yield) was also generated as a dark brown oil. MS (ESI): m/z = 304.0 [M+H] ⁺ Example B.382 6-[[3-methyl-5-(trifluoromethyl)pyrazol-1-yl]methyl]-2-azasp iro[3.3]heptane; 4- methylbenzenesulfonic acid A mixture of tert-butyl 6-[[3-methyl-5-(trifluoromethyl)pyrazol-1-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (generated as regioisomer in B.381, Step a)) (2.3 g, 6.4 mmol) and p-toluenesulfonic acid (2755 mg, 16.0 mmol) in EtOAc (50 mL) was stirred at 25 °C for 24 h. Then the reaction mixture was concentrated and crystallized from MTBE to give the title compound (1468 mg, 3.4 mmol, 53 % yield) as white solid. MS (ESI): m/z = 260.2 [M+H] ⁺ In analogy to Example B.381/B.382, the following regioisomeric pairs of building blocks were generated using the relevant commercial building blocks. Example B.390 6-(1-methylpyrazol-4-yl)oxy-2-azaspiro[3.3]heptane; 4-methylbenzenesulfonic acid To a solution of tert-butyl 6-(1-methylpyrazol-4-yl)oxy-2-azaspiro[3.3]heptane-2-carboxy late (970 mg, 3.31 mmol) in EtOAc (20 mL) was added TsOH (968 mg, 5.62 mmol).Then the mixture was stirred at 80 °C for 16 h. The reaction mixture was concentrated under reduced pressure at 20 °C to afford the crude product. Then to the crude product was added water (15 mL).The solution was lyophilized to afford the title compound (845 mg, 1.57 mmol, 47 % yield) as a yellow gum. MS(ESI): m/z = 194.2 [M-TsOH+H] ⁺ Step a) tert-butyl 6-(1-methylpyrazol-4-yl)oxy-2-azaspiro[3.3]heptane-2-carboxy late To a solution of tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate (1087 mg, 5.1 mmol) and 1-methylpyrazol-4-ol (500 mg, 5.1 mmol) in Toluene (25 mL) was added CMBP ((Cyanomethylene)tributylphosphorane) (6150 mg, 25.5 mmol) under N2 atmoshphere, and the mixture was stirred at 110 °C for 16 h. The mixture was concentrated under vacuum to give a residue, which was purified by flash silica gel chromatography(petroleum ether:ethyl acetate 2:1 to 1:1). The purified solution was concentrated under vacuum to afford the title compound (1000 mg, 3.41 mmol, 67 % yield) was obtained as yellow solid. MS (ESI): m/z = 238.2 [M-C4H8+H] ⁺ Example B.400 3-(2-azaspiro[3.3]heptan-6-ylmethyl)-5-(trifluoromethyl)-1,2 ,4-oxadiazole; 4- methylbenzenesulfonic acid A mixture of tert-butyl 6-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (350 mg, 1.01 mmol) and TsOH (208 mg, 1.21 mmol) in Ethyl acetate (10 mL) was stirred at 80 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was dissolved in MeCN (2.0 mL), water (20.0 mL) and lyophilized to afford the title compound (410 mg, 0.98 mmol, 91% yield) as a white solid. MS (ESI): m/z = 248.0 [M-TsOH+H] ⁺ Step a) tert-butyl 6-[(2Z)-2-amino-2-hydroxyimino-ethyl]-2-azaspiro[3.3]heptane -2-carboxylate To a mixture of hydroxylamine; hydrochloride (2353 mg, 33.9 mmol) in ethanol (25 mL) was added TEA (3426 mg, 33.9 mmol) at 25 °C. After 1 h, tert-butyl 6-(cyanomethyl)-2- azaspiro[3.3]heptane-2-carboxylate (B.349, Step a)) (4000 mg, 16.9 mmol) was added to the reaction mixture, then the reaction was stirred at 50 °C for further 12 h. The reaction was concentrated under reduced pressure to give a residue. The residue was dissolved in water (50 mL), extracted with ethyl acetate (50 mL x 3), and the combined extracts were concentrated under reduced pressure to give the title compound (4.5 g, 16.7 mmol, 99% yield) as a colorless oil, which was used for next step without further purification. MS (ESI): m/z = 270.1 [M+H] ⁺ Step b) tert-butyl 6-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl]-2-azasp iro[3.3]heptane- 2-carboxylate To a solution of tert-butyl 6-[(2Z)-2-amino-2-hydroxyimino-ethyl]-2-azaspiro[3.3]heptane -2- carboxylate (800 mg, 2.97 mmol) in Methanol (20 mL) was added NaOMe (MeOH solution) (1.19 mL, 5.94 mmol) and ethyl trifluoroacetate (2110 mg, 14.9 mmol) at 30 °C. Then the reaction was stirred at 50 °C for 12 h. The reaction was concentrated under reduced pressure to give a residue. The residue was dissolved in water (20 mL), the reaction mixture was extracted with ethyl acetate (10 mL x 3), and the combined extracts were concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC and lyophilized to afford the title compound (360.0 mg, 1.04 mmol, 34.9% yield) as a colorless oil. MS (ESI): m/z = 292.0 [M-C ₄ H ₈ +H] ⁺ Example B.408 6-[[1-(2,2,2-trifluoroethyl)-3-(trifluoromethyl)pyrazol-4-yl ]methyl]-2-azaspiro[3.3]heptane; 4-methylbenzenesulfonic acid To the mixture of tert-butyl 6-[[1-(2,2,2-trifluoroethyl)-3-(trifluoromethyl)pyrazol-4-yl ]methyl]- 2-azaspiro[3.3]heptane-2-carboxylate (1.05 g, 2.46 mmol) in EtOAc (10 mL) was added p- toluenesulfonic acid (465 mg, 2.7 mmol) at 20 °C, then the reaction mixture was stirred at 80 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. Then to the residue was added 20 mL deionized water and 2 mL ACN. The mixture was lyophilized to give the title compound (1224 mg, 2.45 mmol, 99 % yield) as a light yellow oil. MS (ESI): m/z = 328.0 [M+H] ⁺ . Step a) tert-butyl 6-[[1-(2,2,2-trifluoroethyl)-3-(trifluoromethyl)pyrazol-4-yl ]methylene]-2- azaspiro[3.3]heptane-2-carboxylate To the mixture of tert-butyl 6-[[5-(trifluoromethyl)-1H-pyrazol-4-yl]methylene]-2- azaspiro[3.3]heptane-2-carboxylate (B.379, Step a) (2000 mg, 5.83 mmol), cesium carbonate (5694 mg, 17.5 mmol) in DMF (20 mL) was added a solution of 2,2,2-trifluoroethyl trifluoromethanesulfonate (2704 mg, 11.7 mmol) in DMF (2 mL) at 0 °C, and the mixture was stirred at 20 °C for 12 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brince (50 mL) dried over Na ₂ SO ₄ , filtered and concentrated under reduced pressure to give a residue, which was purified by flash silica gel chromatography (Eluent of 0-28% Ethyl acetate/Petroleum ether) to give the title compound (1.1 g, 2.59 mmol, 44 % yield) as a white solid. MS (ESI): m/z = 370.0 [M-C ₄ H ₈ +H] ⁺ . Step b) tert-butyl 6-[[1-(2,2,2-trifluoroethyl)-3-(trifluoromethyl)pyrazol-4-yl ]methyl]-2- azaspiro[3.3]heptane-2-carboxylate To the mixture of tert-butyl 6-[[1-(2,2,2-trifluoroethyl)-3-(trifluoromethyl)pyrazol-4- yl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate (1000 mg, 2.35 mmol) in EtOAc (10 mL) was added Pd/C (300 mg, 10 %, wet.) at 20 °C, then the reaction mixture was stirred at 20 °C for 1 h under H2. The reaction mixture was concentrated under reduced pressure to give tert-butyl 6- [[1-(2,2,2-trifluoroethyl)-3-(trifluoromethyl)pyrazol-4-yl]m ethyl]-2-azaspiro[3.3]heptane-2- carboxylate (1.05 g, 2.46 mmol, 104% yield) as a colorless oil. MS (ESI): m/z = 372.0 [M- C4H8+H] ⁺ . Example B.409 6-[(3-cyclopropyl-1H-pyrazol-5-yl)methyl]-2-azaspiro[3.3]hep tane; 2,2,2-trifluoroacetic acid To a solution of 6-[(3-cyclopropyl-1H-pyrazol-5-yl)methyl]-2-azaspiro[3.3]hep tane-2-carboxylic acid tert-butyl ester (180 mg, 567 µmol) in dichloromethane (2.44 mL) was added TFA (647 mg, 437 µL, 5.67 mmol) and the reaction mixture was stirred at RT for 18 h. Volatiles were removed in vacuo to give 374mg of the crude title compound which was used without further purification, purity approx.50% major contaminant excess of TFA. MS (ESI): m/z = 218.2 [M-TFA+H] ⁺ . Step a) tert-butyl 6-(4-cyclopropyl-2,4-dioxo-butyl)-2-azaspiro[3.3]heptane-2-c arboxylate To a solution of tert-butyl 6-(2-ethoxy-2-oxo-ethyl)-2-azaspiro[3.3]heptane-2-carboxylat e (CAS: 2173992-27-) (2000 mg, 7.06 mmol) in THF (20 mL) was added NaH (791 mg, 19.8 mmol) at 0 °C. After 0.5 h, cyclopropyl methyl ketone (594 mg, 7.06 mmol) was added at 0 °C. The mixture was stirred at 60 °C for 12 h. The reaction mixture was quenched by addition H2O (10 mL) at 25°C, and then diluted with H2O (10 mL) and extracted with EtOAc (10mL x 3). The combined organic layers were washed with sat. aq. NaCl solution (10 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO2, Petroleum ether/Ethyl acetate = 3:1) to give the title compound (600 mg, 1.87 mmol, 26 % yield) as a yellow oil. MS (ESI): m/z = 266.2 [M-C ₄ H ₈ +H] ⁺ . Step b) tert-butyl 6-[(5-cyclopropyl-1H-pyrazol-3-yl)methyl]-2-azaspiro[3.3]hep tane-2- carboxylate To a solution of tert-butyl 6-(4-cyclopropyl-2,4-dioxo-butyl)-2-azaspiro[3.3]heptane-2- carboxylate (540 mg, 1.68 mmol) in Ethanol (5 mL) was added hydrazine (108 mg, 3.36 mmol) at 20 °C and the resulting mixture was stirred at 60 °C for 1 h. The filter liquor was purified by prep-HPLC and lyophilized to give the title comound (458 mg, 1.44 mmol, 77 % yield) as colorless oil. MS (ESI): m/z = 262.1 [M-C ₄ H ₈ +H] ⁺ . Example B.414 5-(2-azaspiro[3.3]heptan-6-ylmethyl)-3-(trifluoromethyl)-1,2 ,4-oxadiazole; 4- methylbenzenesulfonic acid To a solution of tert-butyl 6-[[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (118.0 mg, 0.34 mmol) in EtOAc (2 mL) was added p- toluenesulfonic acid (70.2 mg, 0.41 mmol) at 80 °C and stirred for 12 h. The mixture was concentrated under reduced pressure to give a residue. To the residue was added deionized water and lyophilized to give the title compound (125 mg, 0.3 mmol, 84 % yield) as white solid. MS (ESI): m/z =248.1 [M-TsOH+H] ⁺ Step a) tert-butyl 6-[[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl]-2-azasp iro[3.3]heptane- 2-carboxylate To a solution of tert-butyl 6-(2-ethoxy-2-oxo-ethyl)-2-azaspiro[3.3]heptane-2-carboxylat e (CAS: 2173992-27-1) (300 mg, 1.06 mmol), 2,2,2-trifluoro-N'-hydroxy-acetamidine (CAS: 4314-35-6) in methanol (3 mL) was added sodium methoxide in MeOH solution (5 M) (0.42 mL, 2.12 mmol) at 25°C, then the mixture was stirred at 60 °C for 12 h. The residue was purified by prep- HPLC and lyophilized to give the title compound (120 mg, 0.35 mmol, 33 % yield) as yellow oil. ¹ H NMR (400 MHz, CHLOROFORM-d) δ = 3.96 (s, 2H), 3.85 (s, 2H), 3.06 (d, J = 7.6 Hz, 2H), 2.71 (spt, J = 7.9 Hz, 1H), 2.51 - 2.39 (m, 2H), 2.07 - 1.95 (m, 2H), 1.44 (s, 9H). MS (ESI): m/z =292.0 [M-C4H8+H] ⁺ Example B.415 6-[[2-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)pyrazol-3-yl ]methyl]-2-azaspiro[3.3]heptane; 4-methylbenzenesulfonic acid A solution of p-toluenesulfonic acid (247 mg, 1.43 mmol) and tert-butyl 6-[[2-(2,2,2- trifluoroethyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-az aspiro[3.3]heptane-2-carboxylate (510 mg, 1.19 mmol) in EtOAc (5 mL) was stirred at 80 °C for 12 h. The mixture was concentrated under reduced pressure to give residue. To the residue was added deionized water and lyophilized to give the title compound (550 mg, 1.1 mmol, 92.3% yield) as a colorless oil. MS (ESI): m/z =328.0 [M-TsOH+H] ⁺ Step a) tert-butyl 6-[[2-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)pyrazol-3-yl ]methyl]-2- azaspiro[3.3]heptane-2-carboxylate To a solution of tert-butyl 6-[[5-(trifluoromethyl)-1H-pyrazol-3-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (generated in the synthesis of P.7, Step c)) (1.5 g, 4.34 mmol) in THF (15 mL) was added NaH (261 mg, 6.51 mmol) at 0°C for 0.5 h. Then 2,2,2- trifluoroethyl trifluoromethanesulfonate (2016 mg, 8.69 mmol) was added at 20 °C, and the reaction stirred for 12 h. The reaction was quenched by ice slowly and then extracted with EtOAc (20 mL×3).The combined organic phase was washed with brine (20mL×3), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by prep-HPLC and lyophilized to give regioisomer tert-butyl 6-[[1-(2,2,2-trifluoroethyl)-5- (trifluoromethyl)pyrazol-3-yl]methyl]-2-azaspiro[3.3]heptane -2-carboxylate (240.0 mg, 0.56 mmol, 12.93% yield) (crude) and tert-butyl 6-[[2-(2,2,2-trifluoroethyl)-5- (trifluoromethyl)pyrazol-3-yl]methyl]-2-azaspiro[3.3]heptane -2-carboxylate (800 mg, 1.87 mmol, 43.1% yield) (crude) as yellow solid. The residue was purified by prep-HPLC to give the title compound (530 mg, 1.24 mmol, 66 % yield) as a colorless oil. MS (ESI): m/z =372.0 [M- C4H8+H] ⁺ Example B.416 6-[[1-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)pyrazol-3-yl ]methyl]-2-azaspiro[3.3]heptane; 4-methylbenzenesulfonic acid A solution of p-toluenesulfonic acid (43.5 mg, 0.25 mmol) and tert-butyl 6-[[1-(2,2,2- trifluoroethyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-az aspiro[3.3]heptane-2-carboxylate (regioisomeric product from B.415, Step a)) (90.0 mg, 0.21 mmol) in EtOAc (2 mL) was stirred at 80 °C for 12 h. The mixture was concentrated under reduced pressure to give residue. The residue was added deionized water and lyophilized to give 4-methylbenzenesulfonic acid;6-[[1- (2,2,2-trifluoroethyl)-5-(trifluoromethyl)pyrazol-3-yl]methy l]-2-azaspiro[3.3]heptane (95.4 mg, 0.19 mmol, 88.31% yield) as a off-white solid. MS (ESI): m/z =328.0 [M-TsOH+H] ⁺ ; ¹ H NMR (400 MHz, DMSO-d6) δ = 8.56 - 8.34 (m, 1H), 7.47 (d, J = 8.1 Hz, 3H), 7.11 (d, J = 7.9 Hz, 3H), 6.85 (s, 1H), 5.16 (q, J = 8.8 Hz, 2H), 4.00 - 3.92 (m, 2H), 3.87 - 3.79 (m, 2H), 2.64 (d, J = 7.3 Hz, 2H), 2.48 - 2.35 (m, 2H), 2.34 - 2.30 (m, 1H), 2.29 (s, 4H), 1.95 - 1.86 (m, 2H) Example B.443 6-[[3-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol-5-yl]methyl]-2 -azaspiro[3.3]heptane; 2,2,2- trifluoroacetic acid To a solution of 6-[[5-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol-3-yl]methyl]-2 - azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (155 mg, 430 µmol ) in dichloromethane (2 mL) was added TFA (490 mg, 331 µL, 4.3 mmol) and the reaction mixture was stirred at RT for 18 h. Volatiles were removed in vacuo to yield 318mg of the crude title compound as a viscous yellow oil, purity ~50% major contaminant excess of TFA, which was used without further purification. MS (ESI): m/z =261.2 [M-TFA+H] ⁺ Step a) 6-[[5-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol-3-yl]methyl]-2 -azaspiro[3.3]heptane-2- carboxylic acid tert-butyl ester To a solution of 3,3,3-trifluoropropanehydrazide (CAS: 934171-99-0) (272 mg, 1.91 mmol) and tert-butyl 6-(2-amino-2-imino-ethyl)-2-azaspiro[3.3]heptane-2-carboxyla te; acetic acid (B.349, Step c)) (600 mg, 1.91 mmol) in DMF (5 mL) was added EtONa (195 mg, 2.87 mmol) at 25b°C under N ₂ atmosphere. Then the reaction was stirred at 100 °C under N ₂ atmosphere for 12 h. The reaction was purified by prep-HPLC and lyophilized to afford the title compound (200 mg, 0.55 mmol, 29 % yield) as a white solid. MS (ESI): m/z =361.1 [M+H] ⁺ 1H NMR (400 MHz, METHANOL-d4) δ = 3.92 (s, 2H), 3.80 (s, 2H), 3.67 - 3.50 (m, 2H), 2.84 (br d, J = 7.2 Hz, 2H), 2.57 (td, J = 7.9, 15.6 Hz, 1H), 2.31 (ddd, J = 2.4, 8.0, 10.4 Hz, 2H), 1.98 - 1.91 (m, 2H), 1.42 (s, 9H) Example B.526 5-(2,6-diazaspiro[3.3]heptan-2-ylmethyl)-3-[1-(trifluorometh yl)cyclopropyl]-1,2,4- oxadiazole; trifluoroacetic acid To a solution of 6-[[3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl] methyl]-2,6- diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (231 mg, 595 µmol ) in dichloromethane (1.98 mL) was added TFA (678 mg, 458 µL, 5.95 mmol) and the reaction mixture was stirred at RT for 18 h. Volatiles were removed in vacuo to give 478 mg of the crude desired product as a light yellow viscous oil, purity ~50% major contaminant excess of TFA. The crude was used without further purification. MS (ESI): m/z = 289.2 [M+H] ⁺ Step a) tert-butyl 6-[2-[(Z)-[amino-[1-(trifluoromethyl)cyclopropyl]methylene]a mino]oxy-2-oxo- ethyl]-2,6-diazaspiro[3.3]heptane-2-carboxylate A solution of 2-(2-tert-butoxycarbonyl-2,6-diazaspiro[3.3]heptan-6-yl)acet ic acid (CAS: 1937278-38-0) (1.45 g, 5.66 mmol) and CDI (1.1 g, 6.79 mmol) in DMF (10 mL) was stirred at room temperature for 3 hours. N'-hydroxy-1-(trifluoromethyl)cyclopropanecarboxamidine (CAS: 2172624-76-7) (951 mg, 5.66 mmol) was added to the solution and stirred at 30 °C for 12 h. The reaction was purified by prep-HPLC (water (NH4HCO3)-ACN 27%-57) to afford the title compound (670 mg, 1.65 mmol, 29 % yield) as a white solid. MS (ESI): m/z = 407.1 [M+H] ⁺ ; ¹ H NMR (400 MHz, CHLOROFORM-d) δ = 5.26 (br s, 1H), 4.09 (s, 1H), 4.02 (s, 3H), 3.97 (br s, 1H), 3.54 (s, 4H), 3.48 - 3.39 (m, 2H), 1.44 (s, 9H), 1.40 - 1.10 (m, 4H) Step b) 6-[[3-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-5-yl] methyl]-2,6- diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester A solution of tert-butyl 6-[2-[(Z)-[amino-[1-(trifluoromethyl)cyclopropyl]methylene]a mino]oxy- 2-oxo-ethyl]-2,6-diazaspiro[3.3]heptane-2-carboxylate (600 mg, 1.48 mmol) and Bu ₄ NF (0.37 mL, 0.37 mmol, 0.25 eq) in THF (15 mL) was stirred at 70 °C for 1 h. The reaction was purified by prep-TLC (PE: EtOAc=1:1) to the crude product. The crude product was purified by prep- HPLC (water (FA)-ACN 18%-48%) to afford the title compound (260 mg, 0.67 mmol, 43 % yield) as a yellow solid. MS (ESI): m/z = 389.0 [M+H] ⁺ ; ¹ H NMR (400 MHz, CHLOROFORM- d) δ = 4.00 (s, 4H), 3.81 (s, 2H), 3.52 (s, 4H), 1.52 (br d, J = 3.3 Hz, 2H), 1.48 (br d, J = 3.0 Hz, 2H), 1.42 (s, 9H). Example B.528 6-[(4-methylsulfonylpyrazol-1-yl)methyl]-2-azaspiro[3.3]hept ane; 4-methylbenzenesulfonic acid A mixture of tert-butyl 6-[(4-methylsulfonylpyrazol-1-yl)methyl]-2-azaspiro[3.3]hept ane-2- carboxylate (1.29 g, 3.63 mmol) and p-toluenesulfonic acid (750mg, 4.36 mmol) in EtOAc (50 mL) was stirred at 80 °C for 12 h under N2 balloon. The reaction was concentrated and the residue was dissolved in water (30 mL).The solution was lyophilized to afford the title compound (1.46 g, 3.41 mmol, 90 % yield) as a light yellow solid. MS (ESI): m/z = 256.2 [M+H] ⁺ ; ¹ H NMR (400 MHz, CHLOROFORM-d) δ = 8.58 (br s, 2H), 7.93 (s, 1H), 7.72 (s, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 4.10 - 3.85 (m, 6H), 3.01 (s, 3H), 2.54 (dd, J = 7.9, 15.6 Hz, 1H), 2.28 (s, 3H), 2.25 - 2.15 (m, 2H), 1.95 - 1.86 (m, 2H). Step a) tert-butyl 6-[(4-iodopyrazol-1-yl)methylene]-2-azaspiro[3.3]heptane-2-c arboxylate To a solution of tert-butyl 6-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene]-2 - azaspiro[3.3]heptane-2-carboxylate (45.6 g, 136 mmol), 4-iodopyrazole (24.0 g, 123 mmol), boric acid (7.65 g, 123 mmol) and pyridine (30 mL, 371 mmol) in DCE (230 mL) was added copper diacetate (49.4 g, 247 mmol) under O2 atmosphere.The mixture was stirred at 70 °C for 12 h under O ₂ atmosphere. The reaction was concentrated. The residue was purified by flash chromatography on silica gel eluting with PE/EtOAc (4:1) to afford the crude product, which was purified by prep-HPLC (water(FA)-ACN 55%-75%) to afford the title compound (17.7 g, 44.1 mmol, 35.6 % yield) as a white solid. MS (ESI): m/z = 346.0 [M-C ₄ H ₈ +H] ⁺ Step b) tert-butyl 6-[(4-methylsulfonylpyrazol-1-yl)methylene]-2-azaspiro[3.3]h eptane-2- carboxylate To a solution of tert-butyl 6-[(4-iodopyrazol-1-yl)methylene]-2-azaspiro[3.3]heptane-2- carboxylate (2.0 g, 4.98 mmol, 1.0 eq) in DMSO (30 mL) was added sodium methanesulfonate (1.18 g, 9.97 mmol, 2.0 eq) , Cu(OTf) ₂ (361 mg, 1.0 mmol) and (R,R)-1,2-bis(N- methylamino)cyclohexane (142 mg, 1.0 mmol) at 110 °C for 12 h. The reaction was concentrated and the residue was purified by flash chromatography on silica gel eluting with PE/EtOAc (1:2) to afford the title compound (1.45 g, 4.1 mmol, 82 % yield) as a white solid. MS (ESI): m/z = 298.1 [M-C ₄ H ₈ +H] ⁺ Step c) tert-butyl 6-[(4-methylsulfonylpyrazol-1-yl)methyl]-2-azaspiro[3.3]hept ane-2- carboxylate To a solution of tert-butyl 6-[(4-methylsulfonylpyrazol-1-yl)methylene]-2-azaspiro[3.3]h eptane- 2-carboxylate (1.25 g, 3.54 mmol) in EtOAc (50 mL) was added Pd/C (0.5 g, 0.35 mmol) at 25 °C and stirred for 1 h under H2 balloon (760 mm Hg). The reaction was filtered and concentrated to afford the title compound (1.15 g, 3.24 mmol, 91 % yield) as a white solid. MS (ESI): m/z = 300.3 [M-C ₄ H ₈ +H] ⁺ Example B.529 6-[[4-(trifluoromethylsulfonyl)pyrazol-1-yl]methyl]-2-azaspi ro[3.3]heptane 4- methylbenzenesulfonic acid A mixture of tert-butyl 6-[[4-(trifluoromethylsulfonyl)pyrazol-1-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (630 mg, 1.54 mmol) and p-toluenesulfonic acid (317.97 mg, 1.85 mmol, 1.2 eq) in EtOAc (20 mL) was stirred at 80 °C for 12 h under N2 balloon. The reaction was concentrated and the residue was dissolved in H2O (30 mL).The solution was lyophilized to afford the title compound (738 mg, 1.53 mmol, 97 % yield) as a light yellow solid. MS (ESI): m/z = 310.1 [M+H] ⁺ Step a) tert-butyl 6-[[4-(trifluoromethylsulfanyl)pyrazol-1-yl]methylene]-2- azaspiro[3.3]heptane-2-carboxylate To a solution of tert-butyl 6-[(4-iodopyrazol-1-yl)methylene]-2-azaspiro[3.3]heptane-2- carboxylate (B.528, Step a) (30.0 mg, 0.07 mmol) in ACN (3 mL) was added silver(I) Trifluoromethanethiolate (46.9 mg, 0.22 mmol) , CuI (28.5 mg, 0.15 mmol) and 2-pyridin-2- ylpyridine (23.4 mg, 0.15 mmol) in a sealed tube at 90 °C for 12 h. The reaction was concentrated.The residue was purified by prep-HPLC (water (FA)-ACN] 52%-82%); to afford the title compound (13.0 mg, 0.03 mmol, 46 % yield) as a yellow solid. MS (ESI): m/z = 320.1 [M-C ₄ H ₈ +H] ⁺ Step b) tert-butyl 6-[[4-(trifluoromethylsulfanyl)pyrazol-1-yl]methyl]-2-azaspi ro[3.3]heptane-2- carboxylate To a solution of tert-butyl 6-[[4-(trifluoromethylsulfanyl)pyrazol-1-yl]methylene]-2- azaspiro[3.3]heptane-2-carboxylate (2.8 g, 7.46 mmol) in EtOAc (50 mL) was added Pd/C (1.0 g, 0.75 mmol) at 25 °C and stirred for 1 h under H2 balloon (760 mm Hg). The reaction was filtered and concentrated to afford the title compound (2.8 g, 7.42 mmol, 99 % yield) as a white solid. MS (ESI): m/z = 322.2 [M-C ₄ H ₈ +H] ⁺ Step c) tert-butyl 6-[[4-(trifluoromethylsulfonyl)pyrazol-1-yl]methyl]-2-azaspi ro[3.3]heptane-2- carboxylate To a solution of tert-butyl 6-[[4-(trifluoromethylsulfanyl)pyrazol-1-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (1.0 g, 2.65 mmol) in 1,2-dichloroethane (4 mL), ACN (4 mL) and water (8 mL) was added sodium periodate (1.13 g, 5.3 mmol) and ruthenium(III) chloride hydrate (59.7 mg, 0.26 mmol) at 0 °C, then the mixture was stirred at 25 °C for 12 h. The reaction was concentrated. The residue was purified by prep-HPLC (water(FA)-ACN 50%- 80%) to afford the title compound (630 mg, 1.54 mmol, 58 % yield) as a grey solid. MS (ESI): m/z = 354.3 [M-C ₄ H ₈ +H] ⁺ Example B.530 [1-(2-azaspiro[3.3]heptan-6-ylmethyl)pyrazol-4-yl]-imino-oxo -(trifluoromethyl)-λ⁶-sulfane; 4-methylbenzenesulfonic acid A mixture of tert-butyl 6-[[4-(trifluoromethylsulfonimidoyl)pyrazol-1-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (650 mg, 1.59 mmol) and p-toluenesulfonic acid (329 mg, 1.91 mmol) in EtOAc (10 mL) was stirred at 80 °C for 12 h under N ₂ balloon.The reaction was concentrated and the residue was dissolved in H ₂ O (30 mL).The solution was lyophilized to the title compound (623 mg, 1.3 mmol, 77 % yield) as a light yellow oil. MS (ESI): m/z = 309.1 [M+H] ⁺ Step a) tert-butyl 6-[[4-(trifluoromethylsulfonimidoyl)pyrazol-1-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate A mixture of tert-butyl 6-[[4-(trifluoromethylsulfanyl)pyrazol-1-yl]methyl]-2- azaspiro[3.3]heptane-2-carboxylate (B.529, Step b) (1.8 g, 4.77 mmol), PhI(OAc) ₂ (6.14 g, 19.1 mmol) and NH ₂ COONH ₄ (1.49 g, 19.1 mmol) in TFE was stirred at 30 °C for 12 h. The reaction was concentrated.The residue was purified by prep-HPLC (water (FA)-ACN, 60%-80%) to afford the title compound (650 mg, 1.59 mmol, 33 % yield) as a grey solid. MS (ESI): m/z = 353.1 [M-C ₄ H ₈ +H] ⁺ Example C.10 3-bromo-5-[1-(trifluoromethyl)cyclopropyl]-1H-1,2,4-triazole To a solution of 3-[1-(trifluoromethyl)cyclopropyl]-1H-1,2,4-triazole (5.07 g, 27.2 mmol) in N,N-dimethylformamide (25 mL) was added NBS (10.7 g, 59.8 mmol). The mixture was stirred at 60 °C for 15 h. The reaction mixture was poured into EtOAc and washed with water and brine. The organic layer was dried over Na ₂ SO ₄ and concentrated in vacuo. The crude material was purified by flash chromatography (0% to 20% AcOEt in heptane) to afford the title compound (3.08 g, 42.0%) as a white solid. MS (ESI): m/z = 255.9/257.9 [M+H] ⁺ Step a) (NE)-N-(dimethylaminomethylene)-1-(trifluoromethyl)cycloprop anecarboxamide 1-(trifluoromethyl)cyclopropanecarboxamide (5.0 g, 32.7 mmol) was dissolved in N,N- dimethylformamide dimethyl acetal (27.2 g, 30.4 mL, 229 mmol). The mixture was stirred at RT for 6 h. The reaction mixture was poured into EtOAc and washed with water (three times) and brine. The organic layer was dried over Na2SO4 and concentrated in vacuo to afford the title compound (6.5 g, 90.8%) as yellow amorphous solid. MS (ESI): m/z = 209.1 [M+H] ⁺ Step b) 3-[1-(trifluoromethyl)cyclopropyl]-1H-1,2,4-triazole To a ice cooled solution of (NE)-N-(dimethylaminomethylene)-1- (trifluoromethyl)cyclopropanecarboxamide (6.5 g, 28.1 mmol ) in acetic acid (18 mL) was added hydrazine; hydrate (1.55 g, 1.5 mL, 30.9 mmol). The mixture was stirred at RT for 2 h, then at 50 °C for 2 h. The reaction mixture concentrated in vacuo and dissolved in EtOAc. NaOH 1 N aq. was added (pH 7-8). The mixture was washed with water and brine. The organic layer was dried over Na ₂ SO ₄ and concentrated in vacuo to afford the title compound (5.07 g, 96.8%) as yellow solid. MS (ESI): m/z = 178.1 [M+H] ⁺ Example C.11 4,5-dibromo-2-(2,2,2-trifluoroethyl)triazole To a solution of 4,5-dibromo-2H-triazole (5.0 g, 22.0 mmol) in ACN (50 mL) was added cesium carbonate (7.18 g, 22.0 mmol). Then, 2,2,2-trifluoroethyl trifluoromethanesulfonate (5.12 g, 22.0 mmol) was added dropwise at 0°C. The reactional mixture was stirred for 16h at RT. The reaction mixture was poured into water, EtOAc was added and the aqueous layer was extracted three times with EtOAc. Then, the combined organic layers were washed with water and brine, dried over Na2SO4, filtered off and evaporated. The crude product was purified by column chromatography (silica gel, PE/EtOAc 0-7%). The fractions containing the pure product were combined and evaporated to give 4,5-dibromo-2-(2,2,2-trifluoroethyl)triazole (5.3 g, 17.2 mmol, 77.9% yield) as yellow oil. ¹ H NMR (400 MHz, CHLOROFORM-d) δ = 4.95 (q, J = 7.9 Hz, 2H) Example C.12 3-bromo-1-(2,2,2-trifluoroethyl)-1,2,4-triazole To a solution of 3-bromo-1H-1,2,4-triazole (8000 mg, 54.1 mmol) in THF (80 mL) was added NaH (3.89 g, 97.3 mmol) at 0 °C. After 0.5 h, was added 2,2,2-trifluoroethyl trifluoromethanesulfonate (25.1 g, 108 mmol) and the resulting mixture was stirred at 20°C for 12h. The reaction mixture was poured into water (200 mL) and extracted with EtOAc (200 mL x 3). Combined extracts were washed with brine (150 mL), dried over Na ₂ SO ₄ , filtered, and concentrated under vacuum to give a residue. The residue was purified by prep-HPLC and was concentrated under reduced pressure to give the title compound (6000 mg, 26.1 mmol, 48.3% yield) as brown oil. MS (ESI): m/z = 229.9 [M+H] ⁺ ; ¹ H NMR (400 MHz, CHLOROFORM-d) δ = 12.49 (s, 1H), 9.14 (q, J = 8.1 Hz, 2H) Example C.13 4-dimethylphosphoryl-2-methyl-pyrazole-3-carbaldehyde To a solution of 4-iodo-2-methyl-pyrazole-3-carbaldehyde (CAS: 959986-66-4) (2000 mg, 8.47 mmol) in 1,4-dioxane (20 mL) was added TEA (2.36 mL, 17.0 mmol), dimethylphosphine oxide (794 mg, 10.2 mmol, 1.2 eq), Xantphos (981 mg, 1.69 mmol) and Pd2(dba)3 (776 mg, 0.85 mmol). The reaction mixture was stirred at 70 °C for 12 h under N2 atmosphere. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by reverse flash chromatography (FA condition; MeCN:H2O = 0-30%) and lyophilized to give the title compound as light yellow solid. MS (ESI): m/z = 187.0 [M+H] ⁺ ; ¹ H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.81 (s, 3 H) 1.84 (s, 3 H) 4.25 (s, 3 H) 7.60 (br d, J=1.83 Hz, 1 H) 10.49 (s, 1 H). Example C.17 3-bromo-5-[1-(trifluoromethyl)cyclopropyl]-1H-pyrazole To a solution of 5-[1-(trifluoromethyl)cyclopropyl]-1H-pyrazol-3-amine (2.3 g, 12.0 mmol) in ACN (40 mL) was added a solution of isopentyl nitrite (1.55 g, 13.2 mmol) in ACN (5 mL) dropwise at 0 °C. The reaction was stirred at 0 °C for 1 h. Then CuBr ₂ (1.61 g, 7.22 mmol) was added into the mixture at 0 °C and the resulting mixture was stirred at 20 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by reversed-phase HPLC (water(0.1%FA)-ACN]). The purified solution was lyophilized to afford the title compound (740 mg, 2.9 mmol, 24.1% yield) as a light green solid. MS (ESI): m/z = 257.2 [M+H] ⁺ . Example C.22 1-(3,3,3-trifluoropropyl)pyrazole-3-carbaldehyde To a solution of 1H-pyrazole-3-carbaldehyde (5.0 g, 52.0 mmol) in N,N-dimethylformamide (100 mL) was added 1,1,1-trifluoro-3-iodopropane (17.5 g, 78.1 mmol), Cs2CO3 (33.9 g, 104 mmol, 2.0 eq) and 18-crown-6 (6.88 g, 26.02 mmol, 0.5 eq). The reaction mixture was stirred at 90 °C for 3 h. Then 1,1,1-trifluoro-3-iodopropane (17.5 g, 78.1 mmol) and 18-crown-6 (6.88 g, 26.0 mmol) was added into the mixture and the resulting mixture was stirred at 90 °C for another 60 h.The reaction mixture was poured into water (200 mL) and then extracted with ethyl acetate (100 mLx 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash chromatography on silica gel eluting with PE/EtOAc (3:1) to afford the product 1-(3,3,3-trifluoropropyl)pyrazole-3-carbaldehyde (1.15 g, 5.99 mmol, 12 % yield) as a yellow oil. MS (ESI): m/z = 193.1 [M+H]; ¹ H NMR (400 MHz, CHLOROFORM-d) δ = 9.96 (s, 1H), 7.48 (d, J = 2.1 Hz, 1H), 6.81 (d, J = 2.4 Hz, 1H), 4.46 (t, J = 7.2 Hz, 2H), 2.82 (tq, J = 7.2, 10.2 Hz, 2H). Example C.23 2-[[2-bromo-4-(trifluoromethyl)imidazol-1-yl]methoxy]ethyl-t rimethyl-silane A mixture of trimethyl-[2-[[4-(trifluoromethyl)imidazol-1-yl]methoxy]ethy l]silane (30.0 g, 113 mmol), N-bromosuccinimide (26.1 g, 146 mmol) and AIBN (3.7 g, 22.5 mmol) in Carbon tetrachloride (300 mL) was stirred at 60 °C for 12 h. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by reverse flash (FA condition; MeCN:H ₂ O 0-70%) and lyophilized to afford the title compound (21.0 g, 60.8 mmol, 54 % yield) as a yellow oil. MS (ESI): m/z = 346.9 [M+H] ⁺ ; ¹ H NMR (400 MHz, CHLOROFORM-d) δ = 7.45 (s, 1H), 5.30 (s, 2H), 3.66 - 3.53 (m, 2H), 1.02 - 0.89 (m, 2H), 0.01 (s, 9H) Example 361 A compound of formula (I) can be used in a manner known per se as the active ingredient for the production of tablets of the following composition: Per tablet Active ingredient 200 mg Microcrystalline cellulose 155 mg Corn starch 25 mg Talc 25 mg Hydroxypropylmethylcellulose 20 mg 425 mg Example 362 A compound of formula (I) can be used in a manner known per se as the active ingredient for the production of capsules of the following composition: Per capsule Active ingredient 100.0 mg Corn starch 20.0 mg Lactose 95.0 mg Talc 4.5 mg Magnesium stearate 0.5 mg 220.0 mg